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Malaria is a potentially fatal blood disease with most deaths caused by Plasmodium falciparum. 
It exists in 95 countries worldwide and puts nearly 3.2 billion people at risk of contracting the 
disease. Despite recent advances made in malaria eradication and control including by 
antimalarial drugs (the mainstay of malaria prophylaxis and disease treatment), the need for 
new antimalarials due to antimalarial drug resistance which is on the rise, means that malaria 
research remains an extremely important focus.  
In this study, 21 derivatives of a biologically relevant scaffold, 2,4-diaminoquinazoline, based 
on hits found by high-throughput screening were rationally designed and synthesised using a 
three-step procedure. This involved chlorination of benzoylene urea (1), followed by two 
successive nucleophilic aromatic substitution reactions. The derivatives were purified by 
conventional methods before being fully characterised by NMR, HRMS and IR spectroscopy. 
The derivatives were then tested in vitro for β-haematin inhibition (βHI) using a NP-40 based 
assay and for aqueous solubility using turbidometry. The compounds were also tested for 
biological antimalarial activities in chloroquine sensitive (NF54) and chloroquine resistant 
(DD2) parasites. Cytotoxicity was tested in Chinese Hamster Ovarian cells.  
Of the 21 synthesised quinazoline derivatives 15 were active with IC50 values below 1500 µM 
for βHI and of the 15, ten compounds were similarly active with IC50s below 1500 nM for 
antiplasmodial activity. Three compounds, 13 (NF54), 15 (NF54) and 10 (DD2) possessed 
potent activity below 120 nM against the indicated Plasmodium strains. Resistance and 
selectivity indices indicated that 2,4-diaminoquinazolines were not cross-resistant with 
chloroquine (CQ) and possess selective activity against P. falciparum. On the negative side, 
they possessed poor aqueous solubility, with the majority in the ranges 5-40 µM. In terms of 
structure-activity relationships (SARs), the analysis showed that 2,4 substitutions to the 
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quinazoline scaffold in the forms of linear alkyl, secondary and less rigid amine groups, appear 
to diminish or even abolish activity, whereas substituents such as bulkier aromatics and cyclic 
alkyl groups, activated or inactivated π systems and combinations thereof, improve activity. 
The results have shown that the 2,4-diaminoquinazoline scaffold exerts their activity in the 
form of haemozoin inhibition, decreasing haemozoin levels as well as increasing free haem in 
the malaria parasite at the IC50, much like well-established βHI antimalarial, CQ. Furthermore, 
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This chapter gives a brief overview of malaria, its historical background, global occurrence and 
pathology. It then discusses the relevant organism, Plasmodium, taking a brief look at the 
various stages of the life cycle.  After which it focuses on the blood stage of the life cycle by 
discussing known blood stage inhibiting antimalarials, haemoglobin degradation by the 
parasite and haemozoin formation and inhibition of haemozoin by antimalarials. The 
concluding part of this chapter delves into antimalarial drug resistance, identification of new 
haemozoin inhibiting scaffolds for antimalarials and the scaffold of interest for this project, 
quinazoline. Finally, the aims and objectives of the project are discussed.   
1.1 The history and global occurrence of malaria 
   
The symptoms of malaria have been around for thousands of years. They were reported in  
ancient Chinese medical writings, Nei Ching (The Canon of Medicine), in 2700BC, in Egypt 
3500−4000 years ago and Ancient Greece in 400BC.1 While these reports well-documented 
the symptoms known today as malaria, it was only thousands of years later in 1880 that the 
malaria parasite was first identified by a French surgeon, Charles Louis Alphonse Laveran, in 
the blood of a soldier who suffered from the disease.2 Seventeen years later a British officer in 
the Indian Medical Service, named Ronald Ross, first demonstrated that malaria parasites could 
be transmitted from infected patients to mosquitoes. Ross also later showed that mosquitoes 
could transmit malaria parasites from bird to bird.2 
Until today, the scourge of malaria continues to wreak havoc across the globe. According to 
the World Health Organisation (WHO) in 2015, malaria had ongoing transmission in 95 
countries, which put approximately 3.2 billion people at risk of contracting the blood disease. 
In 2015 malaria claimed the lives of an estimated 438 000 people, approximately 90% of these 
deaths occurring on the continent of Africa (Figure 1.1).3 





Although the facts are undeniably devastating, the WHO has documented a decrease in malaria 
incidence rates globally and within Africa (37% and 42% respectively), between the years 2000 
and 2015. During the same time period, mortality rates diminished by 60% globally and by 
66% within Africa. Currently in an effort to improve upon this situation, the WHO has 
developed the Global Technical Strategy for Malaria 2016-2030 to address remaining 
challenges in global malaria control and elimination, by strategically providing a technical 
framework for all endemic countries as they work towards control and elimination.4 It should 
be noted that though the WHO has documented a decrease in Malaria, it still however remains 
a major concern. 
1.2 Plasmodium, the parasitic protozoan   
Due to the early breakthrough discoveries in the 19th century, malaria is now well understood 
to be an acute febrile blood disease. It is caused by a parasitic protozoan from the genus 
Figure 1.1: Malaria distribution (dark grey regions) across the world.3 




Plasmodium, which is passed onto human beings by the initial host and transmission vector, 
the female Anopheles mosquito.4,5 There are approximately 200 known Plasmodium species, 
five of which cause malaria in humans and of the five, two species namely, Plasmodium 
falciparum and Plasmodium vivax, account for nearly 80% of malaria infections and deaths 
worldwide.6,7 Plasmodium is exclusively an obligate intracellular parasite that grows and 
replicates only within the host cells such as red blood and liver cells respectively, shown 
below.8,9  
1.3   The life cycle of the parasite 
 
The parasite has a complex life cycle, illustrated in Figure 1.2, consisting of three stages, but 




Figure 1.2: The life cycle of the malaria Plasmodium parasite. Copyright © 2012 Cowman et al.10 




The infectious form of Plasmodium (sporozoites), which are located in infected female 
Anopheles mosquito’s salivary glands, gains access to the human bloodstream while the 
mosquito feeds on the human host’s blood, initiating human infection. The sporozoites 
immediately invade the liver of the host where asexual cell division occurs for approximately 
14 days, which produces the haploid form of Plasmodium named merozoites (liver stage). 
Upon lysis of the hepatocytes (liver cells), these haploid cells are released once more into the 
bloodstream of the host where red blood cell (RBC) invasion and infection occurs. During the 
asexual blood stage, the parasite undergoes a two-day cycle of morphological changes which 
include merozoite, ring, trophozoite and schizont stages.11 Not all of the merozoites reproduce 
asexually but some further develop into female and male forms of the parasite called 
gametocytes. After the infected host is bitten by another mosquito, the mosquito ingests the 
gametocytes which undergo sexual reproduction within the mosquito to produce oocysts. These 
oocysts lyse and release sporozoites which migrate to the salivary glands, completing the 
parasitic life cycle.12,13 
While vector controls such as insecticide-treated mosquito nets and indoor residual spraying 
are effective measures for reducing the spread of parasites, alone they are not enough to prevent 
malaria. The backbone of malaria prophylaxis and disease treatment is through the use of 
antimalarial drugs.4 
1.4       Antimalarial drugs  
 
Currently, there are a broad variety of commercially available antimalarial drugs that act on 
different stages of the parasite life cycle; however, the majority of these drugs are active in the 
blood stage. The antimalarials are grouped into specific classes based on their molecular 
structures and modes of action. Table 1.1 summarises the classes of the most widely used blood 
stage inhibitors, giving an example of a commercially available antimalarial for each class.14 




Table 1.1: Classes and examples of well-known blood stage inhibiting antimalarials 

















The mechanisms of malarial inhibition by a number of the blood stage acting drugs are not 
fully understood. Their actions, however, have been extensively studied and it is postulated 




that many exert activity by means of either inhibition of nucleic acid synthesis, induction of 
oxidative stress or inhibition of the haem detoxification pathway.  
The folate antagonist sulfadoxine is a nucleic acid synthesis inhibitor. It has been shown to 
disrupt dihydropteroate synthase, thus preventing the formation of dihydropteroate which is a 
critical molecule for the biosynthesis of folate, which in turn is essential for the biosynthesis 
of deoxyribonucleic acid (DNA). Like sulfadoxine, atovaquone also interrupts DNA 
biosynthesis by inhibiting the function of dihydroorotate dehydrogenase, via inhibition of 
cytochrome bg an enzyme used in electron transport, which consequently halts pyrimidine 
synthesis and hence DNA formation.14,15,16 
The mechanism of action is much less well understood for the endoperoxide, artemisinin. A 
prevailing hypothesis however, is that the antimalarial exerts activity in the form of radical 
activation of haem, Fe(II)PPIX, due to homolytic cleavage of the peroxide-bridge. The 
formation of highly energetic radical species may disrupt membrane function and the overall 
integrity of the parasite. Other theories relate to the ability of the compound to alkylate 
particular protein targets by primarily forming an epoxide at the peroxide bridge, supported by 
epoxides being well-known alkylating agents.14,15,16,17 
The majority of antimalarial drugs form part of the aryl methanol and 4-aminoquinoline drug 
classes which are known to act mainly on the haem disposal pathway of the parasite. These 
compounds inhibit the removal of toxic haem produced as a by-product of haemoglobin 
degradation by the parasite (discussed in section 1.5).14,15,16 The understanding of exactly how 
toxic haem species kill the parasite is still under scrutiny; however, there are two prevailing 
theories: (i) it produces reactive oxygen species, increasing oxidative stress which oxidises 
proteins and lipids and, (ii) due to its lipidophilic nature it destabilises membranes making them 
more permeable.18 




Of the classes of antimalarial drugs discussed, the last has historically been of most interest, 
since the majority of blood stage inhibiting drugs are understood to exert their potency in this 
fashion (inhibition of haem disposal). Therefore, in order to better understand the effects of 
these compounds in the blood stage, a closer look at the RBC is necessary. 
1.5   Haem detoxification pathway by the Plasmodium spp. 
 
Haemoglobin (Hb) is an iron (Fe)-containing metalloprotein in RBCs which is mostly used to 
carry oxygen from the lungs to tissues.19 However for human beings infected with Plasmodium, 
Hb now also becomes essential for parasite survival, with roughly 60 to 80% of the Hb in an 
infected RBC being consumed within the acidic food vacuole (FV) of Plasmodium - for 
nutritional purposes and to free up space in the RBC for the parasite to grow and hide from the 
host immune system.20 
Depending on the phase within the blood stage, the parasite will either engulf Hb, or have it 
transported by endocytotic vesicles into the specialised acidic compartment, the FV. Inside the 
FV, the parasite secretes various digestive enzymes, namely the metalloprotease facilysin, 
histo-aspartic protease, aspartic proteases plasmepsin I, II and IV, and cysteine proteases 
falcipain 1, 2 and 3. These enzymes facilitate the proteolysis of the globin portion of Hb into 
peptides which are later hydrolysed to amino acids for parasite consumption.21,22 Upon the 
degradation of Hb, however, the haem or ferrousprotoporphyrin IX (Fe(II)PPIX) prosthetic 
group is released as a by-product. It is spontaneously oxidised in the aqueous acidic oxygen-
rich environment of the FV into haematin, also called aqua-ferriprotoporphyrin IX (HO-/H2O- 
Fe(III)PPIX) or Fe(III)PPIX for short (Figure 1.4).20,23,24,25 Haematin represents a major danger 
to the parasite because it is lipid soluble and is capable of affecting membrane destruction by 
catalysing Fenton and Haber-Weiss reactions.18 This produces free radicals which increase 
oxidative stress in the parasite, evidently leading to its demise. So in what appears to be a 




detoxification mechanism, Plasmodium very effectively sequesters approximately 95% of the 
Fe(III)PPIX by-product into a microcrystalline form of Fe(III)haem termed haemozoin (HZ), 













It is this process of HZ formation that aryl methanol and 4-aminoquinoline drugs target, which 
is discussed next. 
1.6 Haemozoin formation  
HZ (also referred to as malaria pigment) is an intracellular microcrystalline insoluble form of 
Fe(III)PPIX. It is made by the parasite to avert the toxic and damaging effects of haematin, 
discussed in subsection 1.5. It is well-known that approximately 5-10% of haematin is 
Parasite  













Figure 1.3: A summary of Hb degradation by the malaria parasite. (i) Endocytotic vesicle transportation of Hb 
into the acid food vacuole (FV). (ii) Proteolysis of Hb by digestive enzymes produces Fe(II)PPIX which is rapidly 
oxidised to HO-/H2O-Fe(III)PPIX. (iii) Detoxification of HO-/H2O-Fe(III)PPIX into haemozoin (HZ) 20 
HZ 




detoxified within the parasite by neutralisation with histidine-rich proteins and degradation 
using reduced glutathione; however, approximately 90-95% of haematin has been shown to be 
sequestered into HZ by the Plasmodium species. HZ is formed by a unique reciprocal iron-
oxygen coordinate bond, which links the central iron atom of haematin to the oxygen of the 
propionate moiety of an adjacent haematin molecule. Crystallisation is facilitated by π-stacking 
between porphyrin rings and hydrogen bonding between free propionic acid moieties, Figure 
1.4.26 In terms of external crystal morphology, they differ from organism to organism; however, 
usually taking the form of general rod-like shape with sizes within the range of 300 nm to 1 
µm (Figure 1.4).26 
 
a) b) c)  
 
 
Figure 1.4: (a) The structure of haematin (Fe(III)PPIX) without axial water ligands, illustrating the propionate 
side chains. (b) A structure of HZ, indicating the iron-oxygen coordinate bond and H-bonding. (c) Transmission 
electron microscope image of synthetic HZ Copyright © 2013 Butykai et al.26 
 
The exact mechanism by which haematin is modified into less toxic HZ in order to avoid 
membrane lysis, lipid peroxidation and parasite death, is still incompletely understood. Initially 
haematin was believed to be detoxified into HZ completely by histidine-rich proteins (HRPs); 
however, it has since been shown that Plasmodium laboratory mutants lacking HRP I and II, 
could still effectively form HZ.27 Now it is understood that there are species that actually lack 
orthologues to HRPs but still are capable of HZ formation. This brought about additional 
studies that led to the discovery of a potent haem detoxification protein (HDP) found in 




P.falciparum (PfHDP) by Jani et al.28 The group showed that the parasite secretes HDP into 
the cytosol of the infected RBC and subsequent endocytosis of the cytosol transports HDP to 
the FV, where it was shown that HDP is several times more effective in HZ formation than 
HRPs. Furthermore, recent studies by Chugh et al. and Nakatani et al. have indicated that 
within the FV HDP is functionally coupled with falcipain II and other proteases, and that HDP 
contains two identical haem binding sites which suggests that HDP may bind haem in a ratio 
of 2:1 (haem:HDP).29,30 HDP binding sites contain histidine residues and it has been shown 
that four of the nine residues of HDP are crucial for its function. Hist122 has been postulated 
to axially bind haem while Hist172 and Hist175 sit in the binding site and facilitate binding by 
correctly aligning both species.31,32 This has become a crucial factor in understanding HZ 
formation. 
Alternatively, other experiments strongly support the hypotheses that HZ formation is lipid-
driven as suggested by evidence shown of lipid bodies and phospholipid membranes in close 
proximity with HZ within the acidic food vacuole.27,33,34 Other evidence, has shown that lipids 
promote the formation of β-haematin (synthetic HZ), which is the synthetic, structural and 
chemical equivalent of HZ.33,35,36 Another particularly interesting result has shown that 
amphiphilic detergent molecules which spontaneously form micelles are capable of mediating 
β-haematin formation. Recently Sandlin and co-workers, have shown that multiple detergents 
such as Tween, NP-40, SDS, CHAPS and Triton promote β-haematin formation, albeit with 
different efficiencies. The detergent’s ability to swiftly sequester haematin into the lipophilic 
core, allowing for crystal nucleation to occur, depends on the hydrophilic detergent chain size 
and length.37 This result links to research which has shown that synthetic neutral lipid droplets 
and phospholipids have the ability to form emulsions that facilitate HZ formation.  
The mechanism of HZ formation is still under debate. Furthermore, not only is it important in 
malaria studies, but HZ over the last several years has been discovered in numerous blood-




feeding organisms such as Echinostoma trivolvis, Rhodnius prolixus, Haemoproteus columbae 
and Schistosoma mansoni, which increases its relevance.35  
1.7  Inhibition of haemozoin formation by antimalarials 
Cohen et al. and Macomber et al. suggested that haem was the target of antimalarials as early 
as the 1960s and since then one of the main aspects that has been studied has been drug-
haematin (Fe(III)PPIX) interactions.38,39 Studies have now shown that some of the most well-
known and highly active antimalarials (aryl methanols and 4-aminoquinolines) are understood 
to exert their activity by inhibiting the formation of HZ.  These derivatives are of particular 
interest since some are partner drugs in artemisinin combination therapy (ACT). Furthermore 
new scaffolds that act in similar ways might not only lead directly to new drugs, but also help 
us to understand more about the mechanisms of inhibition, which if revealed might lead to 
major advances being made in the development of new drugs.14,35 
Egan et al. have shown using UV-visible spectroscopic titrations that the quinoline drugs 
associate with Fe(III)PPIX in 40-80% aqueous dimethyl sulfoxide (DMSO).40,41 Using 
chloroquine (CQ), quinine (QN), quinidine (QD), amodiaquine (AQ) and 9-epiquinine they 
were able to determine association constants (log K) ranging from 4.00 – 5.50. UV−visible 
spectroscopic studies utilised the hypochromic effect for the Soret band of Fe(III)PPIX upon 
binding of antimalarial drugs to determine drug-Fe(III)PPIX association constants and 
stoichiometries. Further supporting evidence by Egan et al. showed the in vitro inhibition of β-
haematin formation by the quinoline antimalarials, using a β-haematin inhibition (βHI) test 
assay. Both of the experiments demonstrated drug-Fe(III)PPIX interactions.42   
In 2008, the evidence of drug-Fe(III)PPIX interactions were reinforced by the determination 
of the first ever example of an X-ray crystal structure of Fe(III)PPIX with an antimalarial drug, 
shown by de Villiers et al. The group presented the halofantrine-Fe(III)PPIX X-ray crystal 




structure, showing the deprotonated hydroxyl group of halofantrine coordinated to the iron 
centre of Fe(III)PPIX, while other π-stacking interactions were shown between the Fe(III)PPIX 
porphyrin ring and halofantrine aromatic system.43,44 Four years later, de Villiers et al., 











Figure 1.5: X-ray crystal structures of Fe(III)PPIX-antimalarial complexes. i) quinidine-Fe(III)PPIX and ii) 
quinine-Fe(III)PPIX. Copyright © 2012 K. A. de Villiers et al.45 
 
This work showed that a five coordinate complex formed involving the benzylic alkoxide of 
the compound and the iron core of Fe(III)PPIX, with π-stacking seen between the porphyrin 
system of Fe(III)PPIX and the quinoline moiety of each antimalarial.44,45 
While the evidence presented showed that quinoline and aryl methanol antimalarials interact 
with haem, the mechanism of inhibition of HZ is still under investigation. It has been speculated 
that the formation of a drug-Fe(III)PPIX complex prevents or delays the crystallisation of HZ.  
Research investigations have also shown that CQ forms complexes with both monomeric 
Fe(III)PPIX and µ-oxo dimeric Fe(III)PPIX, and various conditions have been shown to 
influence dimerisation including pH, CQ concentration and lipids. Two models have been 








(Figure 1.6). Model (ii) also postulates involvement of hydrogen bonding interactions between 
the protonated quinoline nitrogen atoms and µ-oxo bridge between the iron centres. While 
formation of the monomeric Fe(III)PPIX species is favoured at low pH and in 40% DMSO, 
CQ has been shown to shift the monomer-dimer equilibrium in favour of the dimer to produce 










Similarly early evidence have shown the significant complexation between QN and 
Fe(III)PPIX that acts differently to CQ-Fe(III)PPIX. Gorka et al. used magnetic susceptibility 
measurements to show that QN interacts predominantly with monomeric Fe(III)PPIX (through 
QN’s oxygen atom of the hydroxyl group) and that the equilibrium shifts from the dimeric 
species to the monomeric, which was linked to antiplasmodial activity.46,47 The group 
conducted a structure activity series showing the importance of the hydroxyl group, rigid ring 
system and aliphatic nitrogen on the ability of QN to form monomeric complex species. Upon 
the removal of these structural features QN lost its ability to complex Fe(III)PPIX and as a 
result lost antiplasmodial activity.47  

















Although the formation of drug-haematin complexes has not been directly shown to be 
responsible for HZ inhibition, their formation has lent support to the proposal that 4-
aminoquinoline, aryl methanols and other antimalarials act by inhibiting HZ formation. An 
alternative hypothesis is that they inhibit the fastest-growing face of the HZ crystal. Which has 
recently become and currently is the favoured idea, which is discussed next. 
In 2008, Weissbuch and Leiserowits described various types of antimalarials, such as 
quinolines, phenanthrene derivatives, and diethylaminoalkoxyxanthones as HZ crystal capping 
agents and showed evidence of their capability to bind stereo-specifically to certain faces (001; 
011; 100) of the crystal, subsequently inhibiting HZ formation and thus the growth of the 






In support of Weissbuch and Leiserowits’ findings, Gildenhuys et al. investigated kinetic 
effects of CQ and QD on the formation of β-haematin using the Avrami equation and 
employing biomimetic lipid−water emulsion conditions. The decreased rate of β-haematin 
formation observed at low concentrations of both drugs was accounted for by supposing a mode 
of drug adsorption to sites on the fastest-growing face of β-haematin.49 
More recently, Olafson et al. used in situ atomic force microscopy to show that β-haematin 
crystallisation follows a classical mechanism in which layers are produced by 2-dimensional 





adsorbed to the 
growth face 
Figure 1.7: An illustration of how HZ inhibitors dock on a particular growing face of HZ. 49 




surface sites were identified (Figure 1.8) that are crucial for crystal growth (dimensional growth 
indicated in Figure 1.8 a) but could be blocked (c), demonstrated by the adsorption of CQ onto 
the surface, therefore slowing down the process of haem detoxification. CQ was shown to 









In addition, the use of molecular docking simulations by Correa de Sousa et al., using Molegro 
Virtual Docker (MVD) (version 2011.5.0), supplied further evidence of the ability of several 
AQ analogues to dock onto the HZ crystal.51 The group showed a relationship between binding 
strength and rotational freedom, demonstrating compounds with greater conformational 
freedom have a greater entropy loss upon binding, and therefore bind weakly.52 
These recent investigations indicate a paradigm shift towards drug-crystal docking as a 
favoured mode in the understanding of HZ inhibition. Understanding the details of the HZ 
inhibition mechanisms of antimalarials and of diverse new HZ-inhibiting scaffolds may thus 
lead to new antimalarial developments. This remains important given the documented reports 
over the last few decades concerning the worldwide rise in antimalarial drug resistance by 
Plasmodium, not only to quinoline and aryl methanol derivatives, but also recently to the potent 
a) Flat segment of growing face b) Newly nucleated islands  
c) Kinks along steps    d) Closely spaced steps   
Figure 1.8: An illustration of the four distinct classes of HZ surface sites. c) Shows the inhibition of crystal 
nucleation and growth by an inhibitor (red). 50 




artemisinin derivatives. Resistance does not however appear to involve a change to the HZ 
formation target, thus this mechanism of action is still of relevance.  
1.8  Antimalarial drug resistance 
In 1967, the WHO defined drug resistance as, “the ability of the parasite strain to survive or 
multiply despite the administration and absorption of a drug given in doses equal to or higher 
than those usually recommended but within the tolerance of the subject…”. 
The appearance of antimalarial drug resistance has been a major obstacle in the global control 
and elimination of malaria.  
The 4-aminoquinoline, CQ, first made in the 1930s, became the most widely used antimalarial 
during the 1960s and 1970s, but today is not of clinical relevance due to CQ resistance by the 
parasite. CQ resistance was first seen in Thailand in 1957; it then spread through Southeast 
Asia and by the 1970s was being detected in Sub-Saharan Africa and South America. New 
antimalarials such as sulfadoxine, pyrimethamine and mefloquine have since been discovered 
in an effort to combat and control resistant strains; however, they too are losing or have lost 
efficacy due to increasing parasite resistance.53 
It was early on during the continuing search for new and safe therapies that the potent 
antimalarial drug, artemisinin, was discovered in China. This compound was extracted from 
the plant Artemisia annua, which had been used for hundreds of years in ancient Asian 
medicine to treat fevers. The discovery led to the synthesis of new antimalarial derivatives of 
artemisinin such as artesunate, artemether and arteether. For the last six years, the 
recommended first-line treatment by the WHO for malaria in vast parts of the world is 
artemisinin combination therapy (ACT) which combines one of the potent artemisinin 
derivatives with another antimalarial.53 Current examples of ACT are: artesunate-mefloquine, 
artesunate-sulfadoxine/pyrimethamine, artemether-lumefantrine and artesunate-AQ. 




Unfortunately in recent years, parasite resistance to the artemisinin derivatives has also been 
detected in five countries, namely: Cambodia, Lao Democratic Republic, Myanmar, Thailand 
and Vietnam, and is still continually spreading.4,3At present, antimalarial drug resistance has 
been documented in various Plasmodium species, namely, P. falciparum, P. vivax and P. 
malariae, with P. falciparum acquiring resistance to nearly all commercially available drug-
therapies, Figure 1.9.4 
 
Figure 1.9: IR Mapper online user interface showing all antimalarial drugs resistance from all vector species 
across the globe recorded from 2005-2016.54 
 
There are two mutated genes associated with quinoline resistance in P. falciparum. The genes 
encode membrane carrier proteins called, P. falciparum P-glycoprotein homologue 1 (PfPgh1) 
and P. falciparum chloroquine-resistance transporter (PfCRT), with PfCRT being the main 
determinant of quinoline resistance.44 These mutations in PfCRT allow the parasite to 
effectively remove CQ and other quinoline derivatives from the intracellular FV by efflux, thus 
rendering these antimalarials ineffective.55,56 It has been shown that a polymorphic change in 
 Confirmed resistance  
 Possible resistance  
 Susceptibility  




the transmembrane domain of PfCRT at position 76 is essential for CQ and quinoline 
resistance. This particular change in PfCRT substitutes the positively charged lysine residue 
for an uncharged threonine residue (K76T) and thus allows doubly protonated, positively 
charged CQ to travel down its electrochemical gradient and out of the acidic FV. It has been 
suggested that P. falciparum possesses these membrane transport proteins within the FV to 
effectively transport peptides and amino acids out of the FV.57,58  
With respect to artemisinin resistance by P. falciparum, research conducted by Mbengue et al. 
have provided recent cellular evidence that the artemisinin derivatives are effective inhibitors 
of Plasmodium falciparum phosphatidylinositol-3-kinases (PfPI3K). These are a collection of 
enzymes primarily understood to partake in general cellular functions such as growth, 
propagation, mobility and intracellular trafficking.59,60 These researchers demonstrated that the 
primary marker of artemisinin resistance, the C580Y Plasmodium falciparum Kelch23 
(PfKelch13) mutation, is capable of limiting proteolysis of PfPI3K, resulting in amplified 
levels of this kinase, resulting in resistance.60  
These briefly discussed mechanisms of quinoline and artemisinin resistance, although still 
under much scrutiny, remain the most plausible within the literature at the moment.  
The ever-emerging resistance towards these antimalarials has led many in the field to turn their 
attention to identifying new antimalarial compounds that may be used to study malaria in all 
aspects and lighten the burden of the disease.  
1.9  New scaffolds for malaria studies 
For decades the scientific community have been searching for novel antimalarials, especially 
potential scaffolds for antimalarials that are structurally different from the well-known classes. 
In 1997, Riscoe and co-workers identified a structurally unique class of potential antimalarial 
derivatives by having revealed that 2,3,4,5,6-pentahydroxyxanthone (X5) inhibited the in vitro 




growth of P.falciparum (CQS and multi-drug resistant strains).61 Over the next few years, this 
group demonstrated important structure-activity relationships (SARs) for a library of 
approximately 50 isomeric hydroxyxanthones, inspired by X5, and showed that these 
compounds exerted their primary antimalarial activity during the erythrocytic cycle of the 
parasite, and that they are β-haematin inhibitors. This important research investigation and 
SARs gave rise to a number of new antimalarial agents.62  
Investigations in the 1980s by Fujioka et al. identified potent acridine alkaloids extracted from 
the Glycosmis, Citrus or Severinia plants, which showed in vitro and in vivo activity against 
rodent malaria.63 This was not the first known acridine derivative that showed potent 
antimalarial activity, since during the 1930s, quinacrine became a medically approved 
antimalarial drug.64 It was much later that further SAR investigations of these scaffolds led to 
the evaluation and lead optimisation of dual-functioning antimalarial acridones (in 2009).65 
Although SAR investigations and natural product extraction screenings, are useful methods for 
the identification of new antimalarial scaffolds, over the last 16 years high-throughput 
screening (HTS) has become one of the topmost tools for the identification of new compounds.  
1.9.1  High throughput screening  
HTS is a very well-established approach to drug discovery that is used widely by 
pharmaceutical industries across the world. Using robotic automation and data processing, 
HTS is a time and cost effective way to assay libraries of millions of molecular compounds to 
assess activities against particular species. The results of these experiments used for drug 
discovery, usually identify ‘hit’ scaffolds of interest, which may be used as a starting point for 
new compound design. 




There have been multiple HTS campaigns focused on βHI for new antimalarial scaffolds 
conducted over several years. In 2000, Kurosawa et al. used a haematin crystallisation assay to 
screen for scaffolds that had better activity than CQ, but were not of the quinoline class. This 
investigation screened over 100000 compounds from several sources (SPECS, Roche cocktails, 
NCC, combinatorial chemistry libraries and microbial broths), which resulted in various 
scaffolds for potential optimisation namely, triarylcarbinol, benzophenone and hydrazine 
derivatives.66 In 2009, a similar HTS study by Rush et al. utilised a colorimetric assay 
established by Ncokazi and Egan, for the primary screening of approximately 16000 
compounds which gave rise to various pyrimidine chemotypes.42,67 Furthermore, additional 
large phenotypic HTS studies conducted by Gamo et al. and Guiguemde et al. in 2010, 
screened over approximately 2 million and 300000 compounds respectively, large portions of 
which came from GlaxoSmithKline’s chemical library.68,69 The screens again utilised 
antiplasmodial assays for inhibitors of P. falciparum (not target specific) in an effort to find 
potential antimalarial pharmacophores.68,69  
The results of a HTS study conducted by Sandlin et al. was used in this project to identify a 
new scaffold for βHI and Plasmodium falciparum inhibition. The Egan group (University of 
Cape Town), in collaboration with the Wright group (Vanderbilt University), have screened 
144330 compounds from the Vanderbilt University Institute of Chemical Biology (VICB) 
library, using two assays, a primary screen to detect βHI and a secondary screen to detect 
inhibition of Plasmodium falciparum growth. This was used to identify hit scaffolds that may 
be of interest.70 
The full library was tested in a 4-nonylphenyl-polyethylene glycol P-40 (Nonidet P-40/NP-40) 
β-haematin formation assay (see experimental methods) which led to the identification of 729 
compounds displaying ≥ 80% β-haematin inhibitory activity. Therefore only potent β-haematin 
inhibitors were determined and this smaller quantity of compounds was suitable for subsequent 




dose-response experiments. Random selections were then made of the initial 729 compounds 
and tested in the βHI assay at a concentration of 0.5-110 μM, which identified false positives 
and assessed the strength of specific compounds against β-haematin formation. 530 compounds 
that exhibited IC50 values ≤ 27 μM against the formation of β-haematin were established as 
hits, having smaller IC50 values than CQ (53.0 μM). The 530 identified compounds were then 
tested in a subsequent screen at a concentration of 23 μM to determine if they were or were not 
active against P. falciparum. Compounds that displayed ≥ 90% inhibition of growth against P. 
falciparum were considered to be hits. The final batch of 171 compounds that inhibited the 
formation and growth of both β-haematin and P. falciparum was subjected to further analysis. 
Of these 171 compounds, 73 showed activity at ≤ 5 μM against P. falciparum. Dose-response 
testing in the multidrug resistant C234 strain identified a further 21 compounds with nanomolar 
activity against P. falciparum and it was consequently from this last batch that the molecular 
parent molecule and proposed scaffold were selected for this project  (Figure 1.10).70 
 
 
Figure 1.10: a) One of the most active screened compounds, with β-haematin inhibition (βHI) and P. falciparum 
(C235) activity IC50 values shown. b) The proposed synthetic scaffold for the project based on the chemotype in 
a).  




Figure 1.10 shows the parent molecule, N2-(4-bromophenyl)-N4-(furan-2-
ylmethyl)quinazoline-2,4-diamine (a), as well as the proposed synthetic scaffold, 2,4-
diaminoquinazoline (b), for this project. The quinazoline structural motif is shown in red.  
1.10  Quinazoline – a pharmacologically relevant compound class 
Quinazoline, named for being an aza derivative of the well-known quinoline, is an organic 
compound that possesses two fused six-membered ring systems, benzene and pyrimidine. This 
scaffold was first synthesised in 1895 by the German chemist August Bischler, although Griess 
had reported the first derivative of quinazoline, 2-cyano-3,4-dihydro-4-oxoquinazoline in 
1869.71  
Presently, substituted quinazoline derivatives have been shown to be extremely 
pharmacologically active and relevant, with there being several commercially available drugs 
for the treatment of cancer, microbial, viral, protozoal and fungal infections, inflammation, 
muscle stiffness, tuberculosis, depression, convulsions and many more indications (Figure 
1.11).72,73  





Figure 1.11: Some examples of commercially available quinazoline derivatives used as drugs in a variety of 
diseases/conditions.  
 
There are numerous reported methods to synthesise quinazolines, including: Niementowski’s 
synthesis of quinazolines using anthranilic acid with formamide, Diels-Alder synthesis 
involving the coupling of an imine to an electron rich alkene, one pot palladium-catalysed 
synthesis by McGowan et al. using an imidamide with halo-aryls and benzaldehyde, zinc-
catalysed five-step synthesis of various imidazole-quinazoline derivatives and aza-Wittig 
synthesis by He et al. using azides and triphenylphosphine in toluene.74,75,76,77 
There is thus an extensive body of research related to the synthesis and biological testing of 
quinazoline derivatives, but to the best of our knowledge none involving the synthesis of 2,4-
diaminoquinazolines as potential antimalarials. This consequently presented an opportunity to 
investigate this unexplored area.  
 
 




 1.10.1  Retrosynthesis of 2,4-diaminoquinazoline  




In the forward synthesis, reductive chlorination of benzoylene urea (SM) by phosphoryl 
oxychloride (POCl3) results in the formation of the precursor, 2,4-dichloroquinazoline (ii). 
Using (ii) in a series of nucleophilic aromatic substitution (SNAr) reactions would result in the 
synthesis of various required mono-substituted quinazoline intermediates (i), which upon 
further SNAr reaction would give rise to the final target compounds (TM). Further discussion 
and details can be found within Chapter 2. 
1.11 Aims and Objectives  
 1.11.1  Aims  
The aims of this research study were to synthesise a series of 2,4-diaminoquinazolines and 
investigate their in vitro antimalarial activity in order to discover structure-activity 
relationships in their antimalarial activity and to evaluate their potential for further optimisation 
and development as antimalarials.  




1.11.2  Objectives  
The specific objectives required to attain the proposed aims were to: 
1. Synthesise derivatives of 2,4-diaminoquinazoline. 
2. Purify the derivatives by flash column chromatography or recrystallisation and quantify 
their purity using high performance liquid chromatography (≥ 95%). 
3. Fully characterise them using high resolution mass spectrometry (HRMS), nuclear 
magnetic resonance (NMR) and infrared spectroscopy (IR)  
4. Determine the βHI IC50s of the derivatives using a NP-40 detergent mediated assay, as 
well as their Pf IC50s, against chloroquine-sensitive NF54 parasites. 
5. Conduct additional in vitro tests on compounds that possess Pf (NF54) IC50s < 1000 
nM, including: 
a. cytotoxicity in a mammalian cell line, 
b. Pf IC50s in the CQ-resistant strain DD2,  
c. aqueous solubility using turbidometry.  
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The synthesis of the target scaffold derivatives mentioned in Chapter 1, namely 2,4-
diaminoquinazolines, was accomplished using a three-step synthetic procedure involving 
chlorination and nucleophilic aromatic substitution reactions. The general procedure for their 
synthesis is presented below, as well as a detailed example for one of them, followed by a 
summary of all the compounds synthesised. The numbering system of the compounds prepared 
is based on structural consistency, rather than strictly adhering to a IUPAC designation in 
which the IUPAC numbering of the quinazoline ring itself is adopted as shown in Figure 2.1. 
 
 
Figure 2.1: IUPAC numbering of the quinazoline ring 
 
2.1  Synthesis of 2,4-dichloroquinazoline (2) 
 
The synthesis of 2,4-dichloroquinazoline, 2, was successfully performed according to the 
general procedure reported by Cho et al., using triethylamine (Et3N) instead of N,N-
diethylaniline as a base (Scheme 2.1).78 The starting material, benzoylene urea, 1, was refluxed 
with phosphoryl oxychloride (POCl3) and Et3N for 18 hours under nitrogen atmosphere. This 











A large excess of POCl3 (10 eq) was needed to form the dichlorinated product, as using 
insufficient equivalents resulted in monochlorination according to nuclear magnetic resonance 
(NMR) spectroscopy. Upon reaction completion, the excess POCl3 was carefully quenched 
using a saturated solution of sodium carbonate (Na2CO3) and the solution then subjected to a 
conventional extraction and purification using column chromatography. Recrystallisation from 
boiling methanol (MeOH) gave 2 in a yield of 87%, whose melting point agreed well with that 
of the literature, m.p. 117-118 °C (Lit 79: 118-120 °C).  
Spectroscopic characterisation was as follows.  Firstly, the infrared (IR) spectrum in Figure 2.2 




















Figure 2.2: IR spectra of compounds 1 and 2  
Wavenumber cm-1 
C=O 






Figure 2.3: 1H NMR spectra of compounds 1 & 2, illustrating a key structural change (a) 
 
In the 1H NMR spectrum of 2 the loss of the amide hydrogen resonances (a) were noted, 
together with a deshielding of the aromatic resonances due to the ring becoming π-deficient. 
The data agreed with that of Cho.78 Similarly, 13C NMR spectroscopy could also be used to 
corroborate the structure. As seen in Figure 2.4, the 13C spectrum showed the anticipated eight 
singlets. However, unequivocal assignments were not made for individual carbons in view of 
their similarity, but rather assigned as either CH or quaternary carbons based on relative 
relaxation (NOE) effects. Indeed, this was a recurring theme throughout the library. The details 











Figure 2.4: 13C NMR spectrum of compound 2 illustrating the correct number of carbon count quaternary (1) and 
tertiary (2) signals  
Finally, a high resolution mass spectrum (HRMS) was recorded using a Waters Synapt G2 
electron spray ionisation (ESI) instrument with an observed mass of 198.9822 which was in 
good agreement with the calculated value of 198.9830 for C8H5Cl2N2 [M+H]+. 
The HRMS results indicated that the [M+H]+ ion was the dominant species, which was not 
surprising in view of the presence of protonatable nitrogen atoms in the structure, where the 
calculated and observed masses agreed well within an acceptable error (25 parts per 10 000). 
Collectively, the data proved the successful synthesis of compound 2. 
For biological evaluation, all the compounds synthesised needed to be ≥ 95% pure, in which 
purification was achieved using flash-column chromatography and recrystallisation 




techniques. Measurement of purity was determined using HPLC conducted using a Agilent 
1220 LC system V. In this manner HPLC purity of 2 was determined to be 99%. 
2.1.1 A proposed mechanism of formation of 2,4-dichloroquinazoline (2) 
 
The proposed mechanism for formation of the monochlorinated intermediate on route to 2 is 
shown in Scheme 2.2. It is understood that the same mechanism would take place at both 









The step labelled (i), shows the attack of the nucleophilic oxygen on the electrophilic 
phosphorus centre of POCl3. This allows for the SNAc-like expulsion of the chloride ion which 
in turn nucleophilically attacks the resultant iminium species (ii), with expulsion of a 
dichlorophosphate leaving group. The same process then repeats at the other carbonyl 
functionality to afford the dichlorinated species, 2,4-dichloroquinazoline, shown in the scheme 
as a bis-salt, which is neutralised on work-up with base (aq. Na2CO3), ultimately to afford 
unprotonated 2.  
Once synthesised, 2 was then used in a series of nucleophilic aromatic substitution reactions to 
afford various intermediate compounds that are discussed in the next section. 
 
 
Scheme 2.2: Proposed half synthesis of 2,4-dichloroquinazoline, 2.  




2.2 Synthesis of 2-chloroquinazoline-4-amine intermediates (3-8) 
The synthesis of mono-substituted 2-chloroquinazoline-4-amine intermediates, 3-8, was 
successfully performed, according to the general methodology reported by Odingo et al.80 by 
way of nucleophilic aromatic substitution (SNAr). Scheme 2.3 represents the general case using 
1-1.7 equivalents of the desired amine and Et3N as base (to neutralise HCl produced) which 







Under these conditions, regioselective substitution at C-4 occurred to afford derivatives 3-8. 
The explanation and proof of regioselectivity will be covered later in section 2.2.1, since this 
is an extremely important aspect of the work.  
The reactions were quenched with ice water before being neutralised with a saturated solution 
of Na2CO3, to remove any HCl salts that may have formed. After extraction with CHCl3 and 
concentration under high vacuum, the intermediates were purified by flash column 
chromatography and recrystallised to afford the pure samples as confirmed by HPLC.  
By way of example, details are given for substitution with furfurylamine (furan-2-
ylmethanamine), Scheme 2.4.  












Following work-up, substituted quinazoline 3 was obtained after chromatography and 
recrystallisation from boiling MeOH in a yield of 50%, whose melting point was sharp  (m.p. 
158-159 °C). Although not a new compound, its melting point was not cited in the literature. 
As an example, the spectroscopic characterisation is presented here which includes the NMR 
spectroscopic and HRMS results, highlighting characteristic features that prove the synthesis 
of compound 3. Similar logical rationalisations were used for all intermediates, 3-8. 
The 1H NMR spectrum of 3, Figure 2.5, showed the presence of both furan resonance peaks, 
as well as those of the quinazoline fragment in the correct relative integration. Notably, the 
furan H-c resonances were observed upfield at around 6.4 ppm, while the furan H-c* resonance 
appeared more downfield as a result of its -relationship to oxygen. A downfield triplet for the 
NH hydrogen at  = 9.2 ppm, coupling to an upfield methylene as a doublet ( = 4.7 ppm), 
confirmed substitution. 





Figure 2.5: 1H NMR spectra of compounds 2 & 3 
 
The 1H NMR spectroscopic chemical shifts agreed with those of the literature presented by 
Odingo et al.80 As before, 13C NMR spectroscopy could also be used to corroborate the 
structure.  
As seen in Figure 2.6, the spectrum showed the anticipated thirteen singlets. However, specific 
assignments were not attempted; rather peaks are divided as before between quaternary (1) and 
non-quaternary (2) carbon atoms, although the two upfield CH carbons at around 110 ppm can 
be safely assigned to the furan ring C-2*, as confirmed by HSQC.  The two types (quaternary 
or non-quaternary) were assigned on the basis of relative relaxation effects (NOE). Indeed, this 
was a recurring theme throughout the library. 










Finally, a HRMS was recorded using a Synapt G2 instrument in which a [M+H]+ peak was 
obtained with an observed mass of 260.0538 which was in good agreement with the calculated 
value of 260.0591 for C13H11ClN3O [M+H]+. 
Collectively, the data proved the successful synthesis of compound 3 at the required purity 
(99.6 %) as shown by the HPLC trace (Figure 2.7). 





































The same characterisation methods and similar rationalisations were used for all the 2-
chloroquinazoline-4-amine intermediates synthesised (3-8). Their structures are shown in 
Table 2.1. 
Table 2.1: The 2-chloroquinazoline-4-amine intermediates (3-8)  
Scaffold  
 


















2.2.1 A proposed mechanism of formation and a proof of regioselectivity for the 
intermediates (3-8) 
Literature reports on the synthesis of products 3-8 via SNAr with various primary and secondary 
amine derivatives indicate that the reaction is regioselective for the 4-position (see Figure 
2.1).81 Hence, in this project 4-regioselectivity was expected. Although no explanation in the 
literature could be found to rationalise this important outcome, one based on a resonance 
argument is shown in Scheme 2.5 using a generalised primary amine involving the classical 
addition/elimination sequence.  Resonance theory suggests that substitution at C-4 provides a 
more stabilised intermediate than that from substitution at C-2. This is because the intermediate 




Meisenheimer-type amidine anion (N-) can delocalise directly into the amidine imine bond 
(C=N) only in the C-4 case, as shown in the scheme.  
 
 
Scheme 2.5: Resonance argument for C-4 regioselectivity 
 
In view of the difficulties in unambiguously assigning regioselectivity using NMR 
spectroscopy data, it was decided to prove the regioselectivity at C-4 for one particular amine 
(cyclohexylamine) used in this project by using X-Ray crystallography. To this end, crystals 
were grown of compound 8, from MeOH and sent for X-ray analysis at The University of Cape 








Figure 2.8: X-ray structure for 2-chloro-N-cyclohexylquinazolin-4-amine, 8 
 
 




The X-Ray structure unambiguously proved a C-4 regioselective substitution. Compound 8 
was shown to crystallise in the Monoclinic C2/c space group, with, a=30.523 (5) b=6.798 (12) 
c=19.261 (3) alpha=90 beta=128 gamma=90. The full details are provided in Appendix A. 
In concluding this subsection, the synthesis of six 2-chloroquinazoline-4-amine products (3-8) 
were successful, and these were then used in a second substitution to afford the final library 
members as discussed in the next section.  
2.3  The synthesis of 2,4-diaminoquinazoline target compounds (9-22) 
The synthesis of 2,4-diaminoquinazoline target compounds, 9-22 were successfully performed 
according to the general methodology reported by van Horn et al., making use of isopropanol 
(i-PrOH) as solvent as opposed to ethanol as suggested by further literature evidence.82,95,96,82,97 
Scheme 2.6 represents the general approach used for the synthesis of these compounds, using 
the previously synthesised intermediates, 3-8, and 1-2 equivalents of the desired amine 









Once the reaction was deemed complete by TLC, the vessel was cooled to ambient temperature 
after which it was neutralised with 1M sodium hydroxide (NaOH) solution and the organic 
product extracted into dichloromethane (DCM)/ ethyl acetate (EtOAc), 50:50. The organic 
phases were then concentrated under high vacuum to reveal the crude product. The compounds 




were purified by flash column chromatography and recrystallised from boiling MeOH to afford 
pure samples as confirmed by HPLC (≥ 95%). A full characterisation of these compounds using 
NMR and HRMS confirmed the identity of the products. 
Scheme 2.7, represents an example of one of the target molecules synthesised, namely N4-
(furan-2-ylmethyl)-N2-phenylquinazoline-2,4-diamine, 9. Characterisation of this compound 









For the synthesis of compound 9, the desired amine utilised was phenylamine (aniline). The 
reaction followed that of the general procedure and required 18 hours to achieve full 
conversion. After completion, as judged by TLC analysis indicating a spot-to-spot conversion, 
a normal workup, extraction and purification by flash column chromatography was conducted. 
Multiple recrystallisations to a constant melting point from boiling MeOH, gave 9 in an overall 
yield of 36% with a m.p. of 103-104 °C. The low overall yield could be attributed to losses 
encountered in there crystallisation steps.  
The spectroscopic characterisation follows. New 1H NMR spectroscopy resonances were noted 
for 9, indicated in red as ‘e’, ‘f ’, ‘f `’ and ‘f `` in Figure 2.9, revealing the introduction of the 
new phenyl ring. Those for the starting material in the reaction, compound 3, are shown in blue 
for comparison. In addition, signals for the furan-2-ylmethanamine substituent at C-4 showed 




that this still remained attached (resonances a, b and c / c*), in which the signals correctly 
integrated for the 6 hydrogen atoms present (three aromatic Hs, one amine H and two 
methylene Hs). Signal ‘a’ represents the amino hydrogen of the amine at C-4, which was 
expected (as before) as a triplet. However, in this case the NH signal could be seen as a broad 
triplet (seen in the enlarged signal ‘a’). Finally, the quinazoline ring hydrogens could also be 
seen as the d signals. Notably, the introduction of the second amine (aromatic) into the 
molecule resulted in resonances being more spread out due to the impact of shielding and 
deshielding effects. 
 
Figure 2.9: 1H NMR spectra of compounds 3 & 9 
 
Overall, the 1H NMR data shown agreed with the literature presented by van Horn et al.82 
Similarly, 13C NMR spectroscopy could also be used to corroborate the structure. As seen in 
Figure 2.10, the spectrum showed the anticipated seventeen singlets for C19H16N4O, taking into 




account the C2-symmetry of the new aniline phenyl ring. As before, no attempt was made to 
categorically assign individual carbon atoms; just to distinguish CH carbons from quaternary 
ones. Since the phenyl hydrogens of the newly introduced aniline moiety could be identified in 




Figure 2.10: 13C NMR spectrum of compound 9  





Figure 2.11: Heteronuclear single quantum coherence (HSQC) spectroscopy for compound 9 
 
For simplicity, only two HSQC signals have been labelled in Figure 2.11, so as to illustrate an 
example of carbon atom identification and less so the entire assignment. The full assignment 
may be seen in the experimental methods section.  
Finally, a HRMS was recorded using a Synapt G2 instrument, with an observed mass of 
317.1393 being obtained which is in good agreement with the calculated value of 317.1402 for 
C19H17N4O [M+H]+. 
Collectively, the various data proved the successful synthesis of compound 9 at the required 





























Figure 2.12: HPLC trace of compound 9 




The same characterisation methods and similar rationalisations were used for all the 2,4-
diaminoquinazoline target compounds synthesised (9-22). Their structures are shown in Table 
2.2. 
Table 2.2: The 2,4-diaminoquinazoline final compounds (9-22)  
Scaffold  
 




























18   
64% 










*The yields calculated here are for the final step of the synthesis and not a cumulative step-wise yield.  




The mechanism of the second substitution is expected to follow the SNAr pathway shown 










In conclusion synthesis of the target scaffold derivatives were successfully accomplished using 
a three-step synthetic procedure, which involved chlorination and nucleophilic aromatic 
substitution reactions. All of the compounds synthesised (Table 2.1 and 2.2) were fully 
characterised by NMR spectroscopic analysis including 1H, 13C, Cosy and HSQC experiments. 
HRMS and IR spectra, together with melting point determinations were used to complete the 
characterisations.  
For biological evaluation all the compounds synthesised needed to be ≥ 95% pure. Purification 
of these compounds was successfully achieved using flash-column chromatography and 
recrystallisation techniques. Measurement of purity was determined using HPLC conducted 
using a Agilent 1220 LC system V and individual purities are quoted in the experimental 
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This chapter discusses the reasoning behind the selection of the quinazoline derivatives 
synthesised and takes a detailed look at various in vitro and biological test results, identifying 
SARs for this scaffold. 
3.1  Sub-structure activity study based on the parent compound (10) 
 
As discussed in Chapter 1, HTS identified the parent quinazoline derivative (10) for this project 
(Figure 3.1). This figure also illustrates the initial sub-structure study conducted to identify 
specific structural features of 10 giving rise to its promising antiplasmodial activity. This was 




Figure 3.1: Sub-structure activity study based on the parent molecule with NF54 Plasmodium falciparum 50% 
inhibitory concentrations (Pf IC50s) shown.  
 




The sub-structure study showed that the activity of 10 depended primarily on the presence of 
the 4-bromoaniline group, since replacing this substituent with a methyl amine group 
completely abolished antiplasmodial activity (12), whereas removal of only furan-2-
ylmethanamine (18) reduced, but did not eliminate activity. This suggests that furan-2-
ylmethanamine may not be essential for activity. Removal of both aromatic substituents (4-
bromoaniline and furan-2-ylmethanamine) completely abolished activity as expected (19). The 
bromo group did not appear to be essential to the activity of 10, since its replacement with a 
hydrogen atom (9) had no effect on the activity.  
Based on the above findings showing the importance of the 4-bromoaniline or aniline groups 
for activity, the synthesis of a doubly substituted 4-bromoaniline moiety was considered to test 
whether this would have enhanced the overall activity, while a doubly substituted furan-2-
ylmethanamine moiety was tested to confirm whether this molecular feature indeed has little 













Figure 3.2: Doubly substituted substituents of the parent molecule 
 




Synthesised compounds 11 and 13 confirmed the importance of the 4-bromoaniline moiety, 
since 13 had drastically improved activity with an IC50 of 80 nM. The lack of potency of the 
furan-2-ylmethanamine moiety in antiparasitic activity was confirmed by compound 11 which 
had a very high IC50 of 786 nM. 13, was thus the most active compound synthesised in the first 
round of SAR investigations, which consequently led to a second structure activity study in an 
effort to determine what features of 13, brought about its strong activity.  
3.2  Sub-structure activity study based on compound 13 
 
It was expected that a sub-structure activity study based on 13 could possibly have led to rapid 
improvement in the activity of the series, as well as further enhance understanding of the SARs 
of the scaffold. Thus the compounds shown in Figure 3.3 were tested. Here the role of 
aromaticity in 13, was assessed.  
 
 
Figure 3.3:  Structural influences in the activity of 13 against NF54 Plasmodium falciparum  




Upon removal of both bromine atoms, compound 14 lost substantial activity (301 nM), which 
led to the hypothesis that electronic effects of the bromine atoms on the aromatic ring systems 
influence activity to some extent. The results also clearly indicated that removal of the 
aromaticity of both substituents greatly diminished activity (16) and that a balance between 
aromaticity and non-aromaticity was required for good activity as seen in compound 15 with 
an activity value of 118 nM. This suggested that derivatives related to 14 and 15, might 
maintain or even improve activity. Thus further questions related to electronics effects and 
nitrogen H-bonding capability on activities were explored. This led to the next set of derivatives 
presented in Figure 3.4. 
 
 
Figure 3.4: The impact of aromatic electronics and nitrogen hydrogen-bonding capacity on the antiplasmodial 
activities against NF54 P.falciparum 
 




Results presented in Figure 3.4, suggested that changing from the electron withdrawing 
bromine substituents which is less releasing (Br is able to back donate through the π system) 
to electron releasing ethoxy groups had no major impact on the activity of the derivatives. It 
was tentatively proposed that these features may allow the aromatic rings to π-stack with 
Fe(III)PPIX, thus inhibiting the formation of HZ, which may be how the compounds exert 
activity. The ability to π-stack with Fe(III)PPIX may however be reduced upon methylation of 
the exo-quinazoline nitrogen atoms which seem to be needed to lock the π-stacked rings in 
place with strong hydrogen bonding interactions. These thoughts were later supported by the 
ability of the compounds to inhibit the formation of β-haematin, using an NP-40 βHI assay. 
Finally, a derivative was made in an effort to improve aq. solubility and hence activity, as it 
was noted in the laboratory that majority of the compounds synthesised were not soluble in aq. 
solution and hence activity might be expected to improve by increasing the aq. solubility of 
these derivatives. The ethylmorpholine group shown in Figure 3.5 was investigated.  
 
Figure 3.5: Influence of solubility and activity of an ethylmorpholine group on quinazoline derivative 15 
 
Aqueous solubilities were determined using a turbidometric 96-well plate assay.83,84 The loss 
of activity in going from compound 15 to 17 (Figure 3.5), probably does not arise from its 




increased aqueous solubility, but rather from the flexible ethyl linker of the ethylmorpholine 
group. Loss of conformational freedom upon interaction with the drug target may be expected 
to result in an entropic penalty that impairs its activity. 
3.3  β-haematin inhibition and comparison with antiplasmodial test results  
Having investigated SARs against P. falciparum, all compounds were tested for βHI. As 
described in Chapter 1, β-haematin is the synthetic, structural and chemical. Equivalent of HZ, 
a microcrystalline form of Fe(III)PPIX made by the parasite to avert the toxic effects of 
haematin. The β-haematin inhibitory effects of quinazoline derivatives were tested using a NP-
40 detergent-mediated assay (see experimental methods).85 
The βHI IC50 and NF54 Pf IC50 results for the entire library of compounds is presented in Table 
3.1. The activity cut off concentrations were set at ≥1500 µM and ≥1500 nM for βHI and PfI 
respectively.  
Table 3.1: βHI & Pf IC50 results with standard errors (n=3) 
Compounds βHI (µM) PfI (nM) 
2 >1500  >1500 
3 >1500 >1500 
4 >1500 >1500 
5 74 ± 5 >1500 
6 522 ± ND >1500 
7 1249 ± ND >1500 
8 145 ± ND >1500 
9 23 ± 2 168 ± 30 
10 15 ± 3 166 ± 40 
11 115 ± 7 786 ± 96 
12 264 ± ND 1053 ± 50 
13 20 ± 2 80 ± 2 
14 39 ± 3 301 ± 26 
15 26 ± 3 118 ± 26 
16 >1500 751 ± 32 
17 >1500 1201 ± 11 
18 25 ± 3 299 ± 40 
19 >1500 >1500 
20 536 ± ND 144 ± 3 
21 166 ± 14 166 ± 6 
22 735 ± ND >1500 
AQ* 17 ± 2 7 ± 3 
*AQ – Amodiaquine86  Parent compound (10) 




Of the 21 synthesised quinazoline derivatives, 15 were active below 1500 µM for βHI and of 
the 15, ten compounds were correspondingly active below 1500 nM for PfI, while the precursor 
(2) and all the intermediates (3-8) were inactive against PfI at the cut-off as illustrated in 
Scheme 3.1. These results strongly suggested that the quinazoline derivatives exert activity by 
HZ inhibition. Indeed, parasite activity was found to be correlated with βHI (Figure 3.6). A 
plot of 1/βHI IC50 vs 1/PfI IC50 gave an R2 value of 0.72, with the exclusion of two clear outliers, 
20 and 21.  
 
 
Further evidence directly supported this mode of action, at least in the case of the most active 
derivative (13). This compound caused a dose-dependent decrease in HZ and an increase in 
free haem, similar to that of the well-established HZ inhibiting antimalarial CQ, described by 
Combrinck et al.87 (The data in Figure 3.7 were kindly provided by Roxanne Openshaw, 
unpublished research). 















Figure 3.6: A linear regression plot (R2 = 0.72) of the correlation between 1/βHI vs 1/PfI IC50 values for the 
entire library of compounds excluding 20 & 21. All values greater than the cut off of 1500 µM/nM were taken as 
zero. 








Figure 3.7: Bar charts indicating biological results for, a) HZ and b) free haem. Control (no drug) 
 
3.4  Additional in vitro test results  
Given the fact that ten of the 21 derivatives had PfI activities less than 1000 nM, with two 
exhibiting values below 100 nM, the series could be considered interesting for further 
development. Consequently, further questions were investigated relating to: a) cross resistance 
in Plasmodium falciparum with CQ, since it could be argued that 2,4-diaminoquinazolines are 
similar to 4-aminoquinoline antimalarials and b) cytotoxicity, since activity against P. 
falciparum could be non-specific.  
Therefore a selection of the most active compounds against the parasite were tested for activity 
against a chloroquine resistant (CQR) strain, DD2, as well as for cytotoxicity against Chinese 















































Table 3.2: PfI DD2 and Cytotoxicity CHO for a selection of the most active PfI NF54 

















9 168 ± 30 198 ± 36 1.2 15.4 ± 1.7 91 5-10 
10 166 ± 40 90 ± 16 0.5 5.3 ± 0.8 32 5-10 
11 786 ± 96 1277 ± 437 1.6 20.0 ± 0.2 25 20-40 
13 80 ± 2 233 ± 8 2.9 4.8 ± 0.2 60 1-5 
14 301 ± 26 416 ± 66 1.4 4.4 ± 0.5 15 5-10 
15 118 ± 26 299 ± 63 2.5 6.4 ± 1.3 54 10-20 
16 751 ± 32 830 ± 381 1.1 6.2 ± 0.8 8 10-20 
18 299 ± 40 209 ± 55 0.7 5.2 ± 0.3 17 10-20 
CQ 5 ± 0.2 152 ± 30 25.5 10  1670 >>100 
 
Results clearly showed that the compounds tested were not cross-resistant with CQ, since they 
displayed low resistance indices in the range 0.5-2.5 compared to 25.5 for CQ. Although most 
compounds showed a marginal loss in activity in DD2 parasites, compound 10 showed an good 
activity increase from 166 nM to 90 nM. The results confirmed that the 2,4-diaminoquinazoline 
scaffold is sufficiently structurally distinct from CQ to make it unsusceptible to CQ resistance 
pathways.  
The results further showed that 2,4-diaminoquinazolines are not merely cytotoxic, since they 
possess selective activity against P. falciparum. The general consensus for a positive (i.e. not 
cytotoxic) result requires a selectivity index greater than 100 as seen for the case of CQ (1670). 
The lower this ratio is, the more cytotoxic a compound is. Here, although not meeting the 
requirements for a drug, the most active compounds were 30-60 times more active against 
malaria parasites than mammalian cells. 
Finally, aqueous solubility ranges shown were also determined (Table 3.2). These revealed that 
these compounds have very poor aqueous solubility in comparison to CQ. This would be an 
area to focus on in event of the further development of this series as potential clinical 
candidates.  
 




3.5  Structure-activity relationships summary  





Scheme 3.1: SAR summary for PfI results, representing levels of structural design A – E. Here alkyl refers to 
non-cyclic groups. 




For several structural designs presented in Scheme 3.1, it may been seen with reference to panel 
D that 2,4 substituents on the quinazoline scaffold in the form of non-cyclic alkyl amines (i), 
tertiary amines (ii) and less rigid amines (iv), appear to diminish activity, whereas panel E 
highlights the facts that bulkier aromatic and cyclic (i, ii), activated or inactivated π systems 
(iii) and combinations thereof (iv), give rise to active quinazolines.  
Collectively, these results indicate that 2,4-diaminoquinazolines are indeed biologically 
relevant and show great potential for future work related to optimisation for antimalarial 
purposes. There is considerable scope for further modification of the scaffold that could 
improve solubility, cytotoxicity and activity in the quest for the next generation of potent 
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4.1  Conclusions 
 
The aims of this research study were to gain insights into the biological activity of the 2,4-
diaminoquinazolines, to discover structure-activity relationships in their antimalarial activity 
and to evaluate their potential for further investigation as potential new antimalarials worthy 
of further optimisation. 
These aims were achieved by synthesising derivatives of the scaffold and studying in vitro β-
haematin inhibition, P. falciparum IC50s in CQ sensitive (NF54) and CQ resistant (DD2) 
parasites, aqueous solubilities, mammalian cytotoxicities in CHO cells and SARs.  
In conclusion, this study has shown that the 2,4-diaminoquinazoline scaffold possesses potent 
antiplasmodial activity by inhibiting the formation of HZ within the blood stage of the parasite 
life cycle. This was shown by the correlation between βHI and Pf IC50 values for the entire 
library of compounds, excluding two outliers (20, 21), and by the dose-dependent decrease in 
HZ and increase in free haem, similar to that of well-established HZ inhibiting antimalarial CQ 
in the case of 13.  
Furthermore, this investigation has shown that 2,4-diaminoquinazoline derivatives have 
several attributes making them suitable for potential future development: firstly, they can be 
made in a three-step, cost-effective synthetic procedure which has obvious commercial benefit; 
secondly, the scaffold has been shown not to be cross-resistant with CQ and that strong 
activities possessed are selective in killing Plasmodium falciparum; lastly, the scaffold 
possesses additional sites that are amenable to variation. These can therefore be exploited to 
improve aqueous solubility and in vitro activities.  
The SAR analysis showed that 2,4-disubstitutions to the quinazoline scaffold in the forms of 
linear alkyl, secondary and less rigid amine groups, appeared to diminish or even abolish 
activity, whereas 2,4-disubstitutions such as bulkier aromatics and cyclic alkyl groups, 




activated or inactivated π systems and combinations thereof, improved activity for the scaffold 
studied. C-4 monosubstitutions of bulkier aromatics and cyclic alkyl groups, activated or 
inactivated π systems and combinations thereof, however appeared to diminish or even abolish 
activity. As a result, sites of activity modulation for the scaffold have been identified on the 




Figure 4.1:  2,4-diaminoquinazoline sites of modulation for βHI and Pf IC50 on the pyrimidine ring 
 
4.2 Future work 
While this research study has uncovered the possible mode of 2,4-diaminoquinazoline 
antimalarial activity and has shown the scaffolds potential to be a serious candidate worth 
future optimisation, there remains important evidence that is lacking and improvements that 
need to be made.  
Computer modelling simulations may be used to support the mode of inhibition discovered in 
this project and to determine the mechanism of HZ inhibition by 2,4-diaminoquinazolines. 
These simulations would aim to illustrate regions of the HZ inhibiting scaffold that interact 
with the fastest-growing faces of the HZ crystal by estimating favourable binding-energies 
associated with these interactions.  
 Site of minor βHI activity modulation   
 Site of major βHI and Pf IC50 activity modulation   




Furthermore, Scheme 4.1 illustrates regions that can be explored to improve aqueous solubility 
and in vitro activity against P. falciparum (a), as well as a proposed route for the synthesis of 




Scheme 4.1:  a) Proposed regions for structural change and b) the synthesis of derivatised 2,4-diaminoquinazoline 
 
 
The proposed structural derivatisation adds one additional step to the general synthesis of the 
2,4-diaminoquinazoline derivatives (iii), making use of cheap commercially available starting 
compounds, urea and 2-aminobenzoic acid derivatives (i). There are > 60 derivatives of 2-
aminobenzoic acid commercially available from Sigma-Aldrich. Of these, there are numerous 
derivatives that may be used to explore hydrophilicity by introducing polar functional 
derivatives to the quinazoline framework such as alcohols, carboxylic acids, amides and 
amines. Some examples are 2-aminobenzene-1,4-dicarboxylic acid, 2,3-diaminobenzoic acid, 
2-amino-3-formylbenzoic acid, 2-amino-3-hydroxybenzoic acid, methyl 2-amino-3-
carboxybenzoate, 2-amino-3-methoxybenzoic acid and 4,6-bianthranilic acid.  
 Site of minor βHI activity modulation   
 Site of major βHI and PfI activity 
modulation   SAR study  




In vitro activities may also be influenced by introducing the above functional groups, bearing 
in mind that certain criteria increase druglikeness. Derivatives that possesses molecular masses 
less than 500 g/mol, no more than five H-bond donors, no more than ten H-bond acceptors and 
a partition coefficient (logP) less than 5, are said to increase druglikeness by generally showing 
better pharmacokinetics (adsorption, distribution, metabolism and excretion) in the human 
body.88 
With great scope for future work optimisation coupled with good results presented in this 
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5.1  Physiochemical methods  
5.1.1 β-Haematin formation assay85 
The compound tested or the control (AQ) were made up in DMSO to a final concentration of 
20 mM, after which 20 µL of the required test compound or control was added to column 12. 
To every well in columns 1-11, 100 µL of a solution containing water, NP-40 (305.5 µM) and 
DMSO at a v/v ratio of 70/20/10 was added. Then, 140 µL and 40 µL of water and NP-40 
(305.5 µM) were added to column 12 respectively. A serial dilution of the test compound was 
then performed across the plate from column 12 through to 1, serially diluting 100 µL 
increments and discarding the increment from column 2, to keep column 1 blank. 178 µL of a 
haemin solution (25 mM)  made in DMSO was added to 20 mL acetate buffer (1M, pH 4.7), 
then 100 µL of this solution was added to every well on the plate, before the plate was then set 
to incubated for approximately 5 hours at 37 °C.  
After incubation, 32 µL of a pyridine solution (20% water, 20% acetone, 10% 2M HEPES & 
50% pyridine) and 60 µL acetone were added to every well on the plate. The plate was then 
measured at 405 nm (SpectraMax M5 plate reader) and analysed using a sigmoidal dose 
response curve on Prism Graph Pad v4.0 to extract the IC50 via non-linear least squares fitting. 
5.1.2 Antimalarial assay  
The screening of the test compounds was conducted in triplicate to accurately determine the in 
vitro antiplasmodial activity against a chloroquine sensitive (CQS) strain of P. falciparum 
(NF54) and against the chloroquine resistant (CQR) strain of P. falciparum (DD2). Continuous 
in vitro cultures of asexual erythrocyte stages of P. falciparum were preserved using an 
improved technique of Trager and Jensen (Trager and Jensen, 2005), while a quantitative 
evaluation of antiplasmodial action in vitro was determined through the lactate dehydrogenase 
assay by means of a revised procedure as reported by Makler et al.89,90 A 20 mg/ml stock 




solution of the test compounds was prepared in 100% DMSO and sonicated to improve 
solubility; however, compounds not completely dissolved were tested as a suspension. A full 
dose-response was completed for all samples to define the concentration preventing 50% of 
parasite growth (IC50 value), with sodium artesunate and CQ used as reference drugs in every 
test performed. The samples were tested at an initial conc. of 100 ng/mL, which was then 
serially diluted two-fold in complete medium to provide ten concentrations (lowest conc. 0.2 
ng/mL). Note, the highest conc. of solvent that the parasites were exposed to had no 
quantifiable consequence on the parasite viability. The data were analysed and the IC50 values 
obtained by plotting a nonlinear dose response curve using Graph Pad Prism v4.0 software. 
5.1.3 Cytotoxicity assay 
The resulting method was used to test the quinazoline derivatives for in vitro cytotoxicity in 
Chinese Hamster Ovarian (CHO) cells, making use of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide assay reported by Mosman et al. and Rubinstein et al.91,92  
A 2 mg/ml stock solution of the test samples (tested in triplicate) were prepared in 10% MeOH 
or 10% DMSO and were tested as a suspension if not properly dissolved, with emetine used as 
the reference drug in all experiments. The primary concentration of emetine (100 µg/ml), was 
serially diluted in complete medium (ten-fold) to provide six concentrations, the lowest being 
0.001 µg/ml. Identical dilution procedures were used to test all compounds. The highest conc. 
of solvent to which the cells were exposed to had no quantifiable consequence on the cell 
viability. The 50% inhibitory concentration (IC50) values were obtained from full dose-
response plots, using a non-linear plot fitting analysis via GraphPad Prism v.4 software. 
 
 




5.1.4 Turbidometric assay  
The procedure was taken from Bevan et al. and Alsenz et al. and has been described briefly 
below.83,84 
The assay was done using a 96-well plate method which involved dissolving the test compound 
in a solvent (usually DMSO) that it was soluble in and then making a serial dilution across a 
‘pre-dilution’ 96-well plate. Aliquots of this solution were added to pH 7.4 phosphate buffered 
saline (PBS) (aqueous solution) to obtain a further serial dilution from which successive 
concentrations were determined. The assay-plate was then left to incubate for 2 hours at 
ambient temperature. The estimated aqueous solubility of the test compound was determined 
from the concentration value above which the test compound precipitated from solution and 
hence caused turbidity.  The measure of turbidity was determined using a UV-visible 
absorbance of the suspension at a wavelength of 620 nm. For this project the compounds 
aqueous solubilities were determined with reference to two controls, hydrocortisone (aq. 
soluble) and reserpine (aq. insoluble).  
5.2  Synthesis  
5.2.1 General 
All chemicals and solvents were bought from Sigma-Aldrich or Fluka and unless otherwise 
specified, were used as received. Tetrahydrofuran (THF) and DCM were freshly distilled under 
nitrogen atmosphere, dried over sodium wire with benzophenone and phosphorus pentoxide 
respectively. Reactions were monitored using TLC pre-coated silica-gel 60 F254 (0.2 mm) 
mounted on aluminium-backed plates, commercially available from Merck. Compounds were 
detected using a UV light with an absorption of 254 nm and stained for visible detection using 
either iodine filings, ninhydrin or anisaldehyde. Purification procedures involved the use of 




flash column chromatography and single or double solvent recrystallisation techniques, using 
a Biotage Isolera Four EXP and analytical reagent grade solvents respectively.  
Characterisation procedures comprised: the determination of the melting points of the 
compounds using a Reichert-Jung Thermovar hot stage microscope; IR spectra recorded on a 
Bruker Tensor 27 FT-IR spectrometer; NMR spectra recorded on Bruker Ultrashield 400 Plus 
(for 1H, 13Cstan, HSQC and COSY). The NMR spec solvents used were deuterated acetone (d-
(CD3)2CO), deuterated dimethyl sulfoxide (d-(CD3)2S=O) and deuterated chloroform (CDCl3) 
with reference peaks occurring at 2.05, 2.50 and 7.26 ppm in the 1H NMR and 29.84, 39.52 
and 77.16 ppm in the 13C NMR spectra respectively.93 All chemical shifts are stated in ppm 
and coupling numbers in hertz (Hz); HPLC was conducted using a Agilent 1220 LC system V; 
HRMS (ESI) was conducted at the University of Stellenbosch, Central Analytical facilities 




















Et3N (1.4 mL, 10 mmol) was added to a suspension of benzoylene urea 1 (0.82 g, 5.1 mmol) 
in POCl3 (9.2 mL, 51 mmol) under inert conditions and set to reflux at 106 °C for 
approximately 18 h. The reaction was monitored using TLC (MeOH/DCM, 1:99, Rf = 0.85) 
until the presence of the starting material diminished, indicating the completion of the reaction. 
After completion, the reaction mixture was diluted with DCM (80 mL) and poured over crushed 
ice, after which the slurry was neutralised using a saturated solution of Na2CO3 (approx. 30 
mL) and allowed to stir for 1 h. The aqueous layer was extracted several times with DCM, after 
which all the DCM fractions were pooled, dried over sodium sulfate (Na2SO4) and the organic 
fraction concentrated under vacuum. The crude material was purified using flash column 
chromatography (MeOH/DCM 1:99, Rf = 0.85), followed by recrystallisation from boiling 
MeOH to obtain compound 2 as a white solid (0.87 g, 87%), m.p. 117-118 °C (Lit 79: 118-120 
°C). 1H NMR (400 MHz, Acetone) δH 8.33 (1H, ddd, J 8.4, 1.4, 0.7 Hz, H-5), 8.16 (1H, td, J 
8.4, 1.4 Hz, H-7), 8.01 (1H, ddd, J 8.4, 1.4, 0.7 Hz, H-8), 7.90 (1H, td, J 8.4, 1.4 Hz, H-6); 13C 
NMR (101 MHz, Acetone) δC 164.5 (C-q), 155.5 (C-q), 153.4 (C-q), 137.5 (C-H), 130.7 (C-
H), 128.7 (C-H), 126.8 (C-H), 123.2 (C-q); HRMS (ESI) m/z: Found 198.9822. Calculated 
198.9830, C8H5Cl2N2 [M+H]+; HPLC purity: 99%. 
 




5.2.3 General Procedure for the synthesis of 2-chloro-quinazolin-4-amine 
intermediates (3-8)80,82,95,96,97 
The following is a general procedure for the synthesis of intermediates (3-8) was followed 
unless otherwise stated in the specific intermediate experimental details. 
The 2-chloro-quinazolin-4-amine intermediates were synthesised on a 0.50-1.0 g scale by 
reacting the preferred amine derivatives (1.1-1.7 eq) with dichloroquinazoline (2, 1.0 eq) and 
Et3N (1.5-2 eq) in THF (10-15 ml) for 3-12 h at 60 °C. 
As previously mentioned in sub-section 5.2.1, TLC was used to monitor the reaction progress 
in combination with UV (254 nm) absorption and staining using iodine, ninhydrin or 
anisaldehyde.  
Upon reaction completion, the reaction vessel was allowed to cool to room temperature before 
the reaction contents were diluted in EtOAc and DCM (50:50), after which the contents were 
neutralised with a saturated solution of Na2CO3 and left to stir for several minutes. The aqueous 
and organic layers were separated and the former washed multiple times with DCM, after 
which the DCM fractions were pooled and concentrated under high vacuum. Chromatography 
of the residue followed by recrystallisation from boiling MeOH or DCM, produced solid 
products that were characterised and evaluated for analytical purity. 
 




2-Chloro-N-(furan-2-ylmethyl) quinazolin-4-amine (3)          
 




Furfurylamine (0.16 mL, 1.8 mmol, 1.1 eq) and Et3N (0.36 mL, 2.5 mmol, 1.5 eq) were added 
to a suspension of 2 (0.34 g, 1.7 mmol) for the synthesis of 3. Compound 3 was purified by 
recrystallisation from boiling MeOH and obtained as a white solid (0.33 g, 50%), m.p. 158-
159 °C, Rf = 0.2 (EtOAc/hexane, 20:80). 1H NMR (400 MHz, DMSO) δH 9.18 (1H, t, J 5.5 Hz, 
H-9), 8.30 (1H, ddd, J 8.4, 1.2, 0.5 Hz, H-5), 7.81 (1H, td, J 8.4, 1.2 Hz, H-7), 7.63 (1H, ddd, 
J 8.4, 1.2, 0.5 Hz, H-8), 7.60 (1H, dd, J 1.8, 0.9 Hz, H-5`), 7.54 (1H, td, J 8.4, 1.2 Hz, H-6), 
6.42 (1H, dd, J 3.2, 1.8 Hz, H-4`), 6.37 (1H, dd, J 3.2, 0.9 Hz, H-3`), 4.74 (2H, d, J 5.5 Hz, H-
10); 13C NMR (101 MHz, DMSO) δC 160.9 (C-q), 156.7 (C-q), 151.2 (C-q), 150.3 (C-q), 142.2 
(C-5`), 133.7 (C-7), 126.6 (C-8), 126.2 (C-6), 123.1 (C-5), 113.4 (C-q), 110.5 (C-4`), 107.7 (C-
3`), 37.3 (C-10); HRMS (ESI) m/z: Found 260.0538. Calculated 260.0591, C13H11ClN3O 














33% Methylamine in ethanol (0.25 mL, 1.8 mmol, 1.1 eq) and Et3N (0.36 mL, 2.5 mmol, 1.5 
eq) were added to a suspension of 2 (0.30 g, 1.5 mmol) for the synthesis of 4. Compound 4 was 
purified by recrystallisation from boiling MeOH and obtained as a white solid (0.26 g, 89%), 
m.p. 207-208 °C, Rf = 0.1 (EtOAc/hexane, 10:90). 1H NMR (400 MHz, DMSO) δH 8.74 (1H, 
q, J 4.3 Hz, H-9), 8.18 (1H, ddd, J 8.4, 1.3, 0.5 Hz, H-5), 7.77 (1H, td, J 8.4, 1.3 Hz, H-7), 7.61 
(1H, ddd, J 8.4, 1.3, 0.5 Hz, H-8), 7.52 (1H, td, J 8.4, 1.3 Hz, H-6), 3.00 (3H, d, J 4.3 Hz, H-
10); 13C NMR (101 MHz, DMSO) δC 161.5 (C-q), 157.0 (C-q), 150.0 (C-q), 133.4 (C-7), 126.6 
(C-8), 126.0 (C-6), 122.8 (C-5), 113.6 (C-q), 27.9 (C-10); HRMS (ESI) m/z: Found 194.0477. 
















4-Bromoaniline (0.50 g, 2.9 mmol, 1.4 eq) and Et3N (0.51 mL, 3.5 mmol, 1.7 eq) were added 
to a suspension of 2 (0.40 g, 2.0 mmol) for the synthesis of 5. Compound 5 was purified by 
recrystallisation from boiling MeOH and obtained as a white solid (0.51 g, 75%), m.p. 167-
168 °C, Rf = 0.3 (EtOAc/hexane, 30:70). 1H NMR (400 MHz, DMSO) δH 10.21 (1H, s, H-9), 
8.55 (1H, ddd, J 8.4, 1.2, 0.5 Hz, H-5), 7.89 (1H, td, J 8.4, 1.2 Hz, H-7), 7.82 – 7.76 (2H, m, 
H-3`, 5`), 7.72 (1H, ddd, J 8.4, 1.2, 0.5 Hz, H-8), 7.65 (1H, td, J 8.4, 1.2 Hz, H-6), 7.63 – 7.59 
(2H, m, H-2`, 6`); 13C NMR (101 MHz, DMSO) δC 159.2 (C-q), 155.9 (C-q), 150.8 (C-q), 
137.6 (C-q), 134.1 (C-7), 131.4 (C-2`, 6`), 126.9 (C-8), 126.6 (C-6), 124.6 (C-3`, 5`), 123.4 
(C-5), 116.5 (C-q), 113.7 (C-q); HRMS (ESI) m/z: Found 333.9713. Calculated 333.9747, 














Aniline (0.26 mL, 2.8 mmol, 1.1 eq) and Et3N (0.53 mL, 3.8 mmol, 1.5 eq) were added to a 
suspension of 2 (0.50 g, 2.5 mmol) for the synthesis of 6. Compound 6 was purified by 
recrystallisation from boiling DCM and obtained as a white solid (0.57 g, 89%), m.p. 187-188 
°C, Rf = 0.3 (EtOAc/hexane, 30:70). 1H NMR (400 MHz, DMSO) δH 10.16 (1H, s, H-9), 8.57 
(1H, ddd, J 8.4, 1.2, 0.5 Hz, H-5), 7.87 (1H, td, J 8.4, 1.2 Hz, H-7), 7.82 – 7.75 (2H, m, H-2`, 
6`), 7.71 (1H, ddd, J 8.4, 1.2, 0.5 Hz, H-8), 7.64 (1H, td, J 8.4, 1.2 Hz, H-6), 7.48 – 7.39 (2H, 
m, H-3`, 5`), 7.22 – 7.18 (1H, m, H-4`); 13C NMR (101 MHz, DMSO) δC 159.4 (C-q), 156.2 
(C-q), 150.8 (C-q), 138.2 (C-q), 134.0 (C-7), 128.6 (C-3`, 5`), 126.8 (C-8), 126.5 (C-6), 124.7 
(C-4`), 123.4 (C-5), 122.9 (C-2`, 6`), 113.7 (C-q); HRMS (ESI) m/z: Found 256.0633. 














N-methylaniline (0.30 mL, 2.8 mmol, 1.1 eq) and Et3N (0.53 mL, 3.8 mmol, 1.5 eq) were added 
to a suspension of 2 (0.50 g, 2.5 mmol) for the synthesis of 7. Compound 7 was purified by 
recrystallisation from boiling MeOH and obtained as a white solid (0.46 g, 66%), m.p. 189-
190 °C, Rf = 0.7 (EtOAc/hexane, 30:70). 1H NMR (400 MHz, DMSO) δH 7.73 – 7.60 (2H, m, 
H-5, 7), 7.51 – 7.47 (2H, m, H-2`, 6`), 7.44 – 7.38 (1H, m, H-4`), 7.38 – 7.34 (2H, m, H-3`, 
5`), 7.08 (1H, ddd, J 8.4, 1.2, 0.5 Hz, H-8), 6.86 (1H, td, J 8.4, 1.2 Hz, H-6), 3.58 (3H, s, H-
10); 13C NMR (101 MHz, DMSO) δC 162.0 (C-q), 155.3 (C-q), 152.3 (C-q), 146.4 (C-q), 132.6 
(C-7), 129.8 (C-3`, 5`), 127.1 (C-8), 126.9 (C-6), 125.8 (C-2`, 6`), 125.6 (C-5), 124.7 (C-4`), 
114.2 (C-q), 42.0 (C-10); HRMS (ESI) m/z: Found 270.0798. Calculated 270.0798, 















Cyclohexylamine (0.31 mL, 2.8 mmol, 1.1 eq) and Et3N (0.53 mL, 3.8 mmol, 1.5 eq) were 
added to a suspension of 2 (0.50 g, 2.5 mmol) for the synthesis of 8. Compound 8 was purified 
by recrystallisation from boiling MeOH and obtained as a white solid (0.63 g, 96%), m.p. 154-
155 °C, Rf = 0.4 (EtOAc/hexane, 30:70). 1H NMR (400 MHz, DMSO) δH 8.33 (1H, ddd, J 8.4, 
1.3, 0.4 Hz, H-5), 8.30 (1H, d, J 7.8, Hz, H-9), 7.75 (1H, td, J 8.4, 1.3 Hz, H-7), 7.58 (1H, ddd, 
J 8.4, 1.3, 0.4 Hz, H-8), 7.49 (1H, td, J 8.4, 1.3 Hz, H-6), 4.16 – 4.04 (1H, m, H-1`), 1.99 – 
1.03 (8H, m, H-2`, 3`, 5`, 6`), 1.68 – 1.57 (1H, m, H-4`), 1.23 – 1.03 (1H, m, H-4`); 13C NMR 
(101 MHz, DMSO) δC 160.1 (C-q), 157.0 (C-q), 150.3 (C-q), 133.4 (C-7), 126.5 (C-8), 125.7 
(C-6), 123.3 (C-5), 113.4 (C-q), 49.7 (C-q), 31.7 (CH2 ×2), 25.2  (CH2), 24.8 (CH2 ×2); HRMS 











5.2.4  General Procedure for the synthesis of 2,4-diaminoquinazoline final 
derivatives (9-22)80,82,96,98 
The following is a general procedure for the synthesis of the final compounds (9-22) and was 
followed unless otherwise stated in the specific experimental details.  
The quinazoline-2,4-diamine final compounds (9-22) were synthesised on a 0.05 – 0.30 g scale 
by reacting the required 2-chloro-quinazolin-4-amine intermediate (1 eq) with the desired 
amine compound  (1 - 2 eq) in a sealed tube overnight at a temperature of 150 °C in isopropanol 
(2-5 mL). TLC was used to monitor the reactions in combination with UV (254 nm) absorption 
and staining using iodine, ninhydrin or anisaldehyde.  
Upon reaction completion, the reaction contents were allowed to cool to ambient temperature 
before being diluted with EtOAc, after which they were neutralised with a solution of NaOH 
(1 M, 3-4 ml), which was allowed to stir for several minutes. The aqueous and organic layers 
were separated and the former washed multiple times with EtOAc, after which the EtOAc 
fractions were pooled and concentrated under high vacuum. Chromatography of the residue, 
followed by recrystallization from boiling MeOH or DCM, produced solid products that were 















Phenylamine (0.11 mL, 1.2 mmol, 1.2 eq) was reacted with compound 3 (0.26 g, 1.0 mmol) 
for the synthesis of 9. Compound 9 was purified by recrystallisation from boiling MeOH and 
obtained as a white solid (0.11 g, 36%) m.p. 103-104 °C, Rf = 0.4 (EtOAc/hexane, 30:70). 1H 
NMR (400 MHz, DMSO) δH 9.10 (1H, s, H-9), 8.64 (1H, t, J 5.6 Hz, H-9`), 8.12 (1H, dd, J 
8.4, 1.0 Hz, H-5), 7.86 (2H, dd, J 8.6, 1.0 Hz, H-2``, 6``), 7.62 (1H, td, J 8.4, 1.0 Hz, H-7), 7.59 
(1H, dd, J 1.8, 0.8 Hz, H-5`), 7.43 (1H, dd, J 8.4, 1.0 Hz, H-8), 7.29 – 7.23 (2H, m, H-3``, 5``), 
7.19 (1H, td, J 8.4, 1.0 Hz, H-6), 6.95 – 6.86 (1H, m, H-4``), 6.40 (1H, dd, J 3.2, 1.8 Hz, H-
4`), 6.36 (1H, dd, J 3.2, 0.8 Hz, H-3`), 4.78 (2H, d, J 5.6 Hz, H-11); 13C NMR (101 MHz, 
DMSO) δC 159.8 (C-q), 156.4 (C-q), 152.3 (C-q), 150.4 (C-q), 141.9 (C-5`), 141.0 (C-q), 132.8 
(C-7), 128.2 (C-2``, 6``), 124.8 (C-8), 122.8 (C-5), 121.6 (C-6), 120.8 (C-4``), 118.9 (C-3``, 
5``), 111.5 (C-q), 110.4 (C-4`), 107.1 (C-3`), 37.2 (C-11); HRMS (ESI) m/z: Found 317.1393. 
Calculated 317.1402, C19H17N4O [M+H]+; HPLC purity: 97%. 
 











4-Bromoaniline (0.25 g, 1.4 mmol, 1.4 eq) was reacted with compound 3 (0.26 g, 1.0 mmol) 
for the synthesis of 10. Compound 10 was purified by recrystallisation from boiling MeOH and 
obtained as a pale-brown solid (0.30 g, 78%) m.p. 161-162 °C, Rf = 0.7 (EtOAc/hexane, 80:20). 
1H NMR (400 MHz, DMSO) δH 9.20 (1H, s, H-9), 8.58 (1H, t, J 5.6 Hz, H-9`), 8.12 (1H, dd, 
J 8.4, 1.2 Hz, H-5), 7.91 – 7.85 (2H, m, H-3``, 5``), 7.61 (1H, td, J 8.4, 1.2 Hz, H-7), 7.59 (1H, 
dd, J 1.8, 0.8 Hz, H-5`), 7.43 (1H, dd, J 8.4, 1.2 Hz, H-8), 7.42 – 7.37 (2H, m, H-2``, 6``), 7.19 
(1H, td, J 8.4, 1.2 Hz, H-6), 6.40 (1H, dd, J 3.2, 1.8 Hz, H-4`), 6.37 (1H, dd, J 3.2, 0.8 Hz, H-
3`), 4.78 (2H, d, J 5.6 Hz, H-11); 13C NMR (101 MHz, DMSO) δC 159.9 (C-q), 156.5 (C-q), 
152.3 (C-q), 151.1 (C-q), 141.9 (C-5`), 140.8 (C-q), 132.7 (C-7), 130.9 (C-2``, 6``), 125.4 (C-
8), 122.8 (C-5), 121.7 (C-6), 120.4 (C-3``, 5``), 111.7 (C-q), 111.7 (C-q), 110.5 (C-4`), 107.0 
(C-3`), 37.2 (C-11); HRMS (ESI) m/z: Found 395.0506. Calculated 395.0507, C19H16BrN4O 
[M+H]+; HPLC purity: 99%. 
 












Furfurylamine (0.073 mL, 0.81 mmol, 1.1 eq) was reacted with compound 3 (0.19 g, 0.73 
mmol) for the synthesis of 11, which was purified by flash chromatography, Rf = 0.3 
(MeOH/DCM, 10:90), and obtained as a pale-yellow solid (0.16 g, 66%), m.p. 116-117 °C. 1H 
NMR (400 MHz, DMSO) δH 8.43 – 8.26 (1H, m, H-9/ 9`), 8.01 (1H, dd, J 8.4, 1.3 Hz, H-5), 
7.55 (1H, d, J 1.8 Hz, H-5`/ 5``), 7.52 (1H, d, J 1.8 Hz, H-5`/ 5``), 7.48 (1H, td, J 8.4, 1.3 Hz, 
H-7), 7.27 (1H, dd, J 8.4, 1.3 Hz, H-8), 7.04 (1H, td, J 8.4, 8.4, 1.3 Hz, H-6), 7.00 – 6.89 (1H, 
m, H-9/ 9`), 6.38 (1H, dd, J 3.2, 1.8 Hz, H-4`/4``), 6.35 (1H, dd, J 3.2, 1.8 Hz, H-4`/4``), 6.32 
(1H, dd, J 3.2, 0.8 Hz, H-3`/3``), 6.22 (1H, dd, J 3.2, 0.8 Hz, H-3`/3``), 4.70 (2H, d, J 5.5 Hz, 
H-10/10`), 4.54 (2H, d, J 5.5 Hz, H-10/10`); 13C NMR (101 MHz, DMSO) δC 159.8 (C-q), 
158.8 (C-q), 154.1 (C-q), 152.6 (C-q), 151.7 (C-q), 141.8 (C-Ar), 141.4 (C-Ar), 132.3 (C-7), 
124.7 (C-8), 122.7 (C-5), 120.3 (C-6), 111.1 (C-q), 110.4 (C-Ar), 110.3 (C-Ar), 107.1 (C-Ar), 
106.2 (C-Ar), 37.6 (CH2), 36.8 (CH2); HRMS (ESI) m/z: Found 321.1342. Calculated 
















33% Methylamine in ethanol (0.079 mL, 0.62 mmol, 1.1 eq) was reacted with compound 3 
(0.15 g, 0.58 mmol) for the synthesis of 12, which was purified by flash chromatography, Rf = 
0.3 (MeOH/DCM, 8:92), and obtained as a pale-yellow solid (0.076 g, 51%),  m.p. 203-204 °C 
(Lit 82: 205 °C ). 1H NMR (400 MHz, DMSO) δH 8.39 – 8.31 (1H, m, H-9`), 8.01 (1H, dd, J 
7.9, 1.3 Hz, H-5), 7.56 (1H, dd, J 1.8, 0.8 Hz, H-5`), 7.49 (1H, td, J 7.9, 1.3 Hz, H-7), 7.28 
(1H, dd, J 7.9, 1.3 Hz, H-8), 7.03 (1H, td, J 7.9, 1.3 Hz, H-6), 6.58 (1H, q, J 4.1 Hz, H-9), 6.39 
(1H, dd, J 3.2, 1.8 Hz, H-4`), 6.33 (1H, dd, J 3.2, 0.8 Hz, H-3`), 4.69 (2H, d, J 5.4 Hz, H-10), 
2.84 (3H, d, J 4.1 Hz, H-11); 13C NMR (101 MHz, DMSO-d6) δC 159.5 (C-q), 159.2 (C-q), 
152.6 (C-q), 151.1 (C-q), 141.8 (C-5`), 132.2 (C-7), 124.1 (C-8), 122.8 (C-5), 120.1 (C-6), 
110.9 (C-q), 110.4 (C-4`), 107.1 (C-3`), 36.9 (C-10), 27.8 (C-12); HRMS (ESI) m/z: Found 



















4-Bromoaniline (0.17 g, 1.0 mmol, 1.3 eq) was reacted with  compound 5 (0.25 g, 0.75 mmol) 
for the synthesis of 13, which was purified by recrystallisation from boiling MeOH and 
obtained as a light-brown solid (0.29 g, 82%), m.p. 183-184 °C, Rf = 0.6 (EtOAc/hexane, 
50:50). 1H NMR (400 MHz, DMSO) δH 9.69 (1H, s, H-9/9`), 9.31 (1H, s, H-9/9`), 8.38 (1H, 
dd, J 7.5, 1.2 Hz, H-5), 7.92 – 7.88 (4H, m, H-2`, 2``, 6`, 6``), 7.69 (1H, td, J 7.5, 1.2 Hz, H-
7), 7.57 (2H, d, J 8.9 Hz, H-3`, 5`/ 3``, 5``), 7.52 (1H, dd, J 7.5, 1.2 Hz, H-8), 7.41 (2H, d, J 
8.9 Hz, H-3`, 5`/ 3``, 5``), 7.31 (1H, td, J 7.5, 1.2 Hz, H-6); 13C NMR (101 MHz, DMSO) δC 
158.2 (C-q), 155.9 (C-q), 151.4 (C-q), 140.5 (C-q), 138.8 (C-q), 133.1 (C-7), 131.2 (C-Ar ×2), 
130.9 (C-Ar ×2), 125.7 (C-8), 124.4 (C-Ar ×2), 123.1 (C-5), 122.2 (C-6), 120.7 (C-Ar ×2), 
115.2 (C-q), 112.1 (C-q), 111.8 (C-q); HRMS (ESI) m/z: Found 468.9663. Calculated 


















Aniline (0.064 mL, 0.70 mmol, 1.2 eq) was reacted with compound 6 (0.15 g, 0.59 mmol) for 
the synthesis of 14, which was purified by recrystallisation from boiling MeOH and obtained 
as a white solid (0.092 g, 52%), m.p. 70-71 °C (Lit 99: 75 °C), Rf = 0.4 (MeOH/DCM, 8:92). 
1H NMR (400 MHz, DMSO) δH 9.57 (1H, s, H-9/ 9`), 9.12 (1H, s, H-9/ 9`), 8.40 (1H, dd, J 
8.2, 1.3 Hz, H-5), 7.94 (2H, d, J 7.7 Hz, H-2`, 6`/ 2``, 6``) 7.89 (2H, d, J 7.7 Hz, H-2`, 6`/ 2``, 
6``), 7.67 (1H, td, J 8.2, 1.3 Hz, H-7), 7.51 (1H, dd, J 8.2, 1.3 Hz, H-8), 7.45 – 7.37 (2H, m, H-
3`, 5`/ 3``, 5``), 7.29 (1H, td, J 8.2, 1.3 Hz, H-6), 7.26 – 7.22 (2H, m, H-3`, 5`/ 3``, 5``), 7.15 
(1H, t, J 7.4 Hz, H-4`/ 4``), 6.91 (1H, t, J 7.4 Hz, H-4`/ 4``); 13C NMR (101 MHz, DMSO) δC 
158.4 (C-q), 156.4 (C-q), 151.7 (C-q), 141.1 (C-q), 139.4 (C-q), 132.9 (C-7), 128.4 (C-Ar ×2), 
128.2 (C-Ar ×2), 125.6 (C-8), 123.4 (C-Ar), 123.1 (C-5), 122.4 (C-Ar ×2), 121.8 (C-6), 120.8 
(C-Ar), 118.9 (C-Ar ×2), 111.8 (C-q); HRMS (ESI) m/z: Found 313.1441. Calculated 313.1453 















Cyclohexylamine (0.11 mL, 0.89 mmol, 1.2 eq) was reacted with compound 6 (0.20 g, 0.78 
mmol) for the synthesis of 15, which was purified by flash chromatography, Rf = 0.3 
(EtOAc/Hexane, 30:70) as a white solid (0.18 g, 72%), m.p. 133-134 °C. 1H NMR (400 MHz, 
DMSO) δH 9.35 (1H, s, H-9/ 9`), 8.28 (1H, dd, J 8.0, 1.2 Hz, H-5), 7.96 (2H, d, J 7.9 Hz, H-
2`, 6`), 7.54 (1H, td, J 8.0, 1.2 Hz, H-7), 7.35 (2H, t, J 7.9 Hz, H-3`, 5`), 7.30 (1H, dd, J 8.0, 
1.2 Hz, H-8), 7.15 – 7.03 (2H, m, H-4`, 6), 6.57 (1H, s, H-9/ 9`), 3.79 (1H, s, H-1``), 1.94 – 
1.29 (8H, m, H-2``, 3``, 5``, 6``), 1.61 – 1.58 (1H, m, H-4``), 1.21 – 1.17 (1H, m, H-4``); 13C 
NMR (101 MHz, DMSO) δC 158.1 (C-q), 158.0 (C-q), 152.4 (C-q), 139.8 (C-q), 132.5 (C-7), 
128.2 (C-3`, 5`), 124.6 (C-8), 123.0 (C-6), 122.8 (C-5), 121.5 (C-2`, 6`), 120.1 (C-4`), 110.9 
(C-q), 49.2 (C-q), 32.8 (CH2 ×2), 25.4 (C-4``), 25.0 (CH2 ×2); HRMS (ESI) m/z: Found 














Cyclohexylamine (0.073 mL, 0.63 mmol, 1.1 eq) was reacted with compound 10 (0.15 g, 0.57 
mmol) for the synthesis of 16, which was purified by flash chromatography, Rf = 0.3 
(EtOAc/Hexane, 30:70), and obtained as a white solid (0.13 g, 69%), m.p. 148-149 °C. 1H 
NMR (400 MHz, DMSO) δH 8.02 (1H, dd, J 8.2, 1.1 Hz, H-5), 7.44 (1H, td, J 8.2, 1.1 Hz, H-
7), 7.19 (1H, dd, J 8.2, 1.1 Hz, H-8), 6.98 (1H, td, J 8.2, 1.1 Hz, H-6), 6.50 – 6.09 (1H, m, H-
9/ 9`), 4.19 – 3.99 (1H, m, H-1`/1``), 3.87 – 3.69 (1H, m, H-1`/1``), 2.03 – 0.98 (20H, m, 2`-
6`, 2``-6``); 13C NMR (101 MHz, DMSO) δC 159.0 (C-q), 158.5 (C-q), 151.6 (C-q), 132.0 (C-
7), 124.0 (C-8), 122.9 (C-5), 119.4 (C-6), 110.8 (C-q), 49.2 (C-1`/1``), 32.8 (CH2 ×2), 32.2 
(CH2 ×2), 25.5 (CH2), 25.4 (CH2), 25.2 (CH2 ×2), 25.0 (CH2 ×2); HRMS (ESI) m/z: Found 
















4-(2-Aminoethyl)morpholine (0.071 mL, 0.52 mmol, 1.1 eq) was reacted with compound 6 
(0.12 g, 0.46 mmol) for the synthesis of 17,which was purified by flash chromatography, Rf = 
0.25 (MeOH/DCM, 10:90), and obtained as a pale-yellow solid (0.12 g, 71%), m.p. 145-146 
°C.1H NMR (400 MHz, CDCl3) δH 7.79 – 7.71 (3H, m, H-5, 2`, 6`), 7.57 (1H, td, J 8.2, 1.3 Hz, 
H-7), 7.49 (1H, dd, J 8.2, 1.3 Hz, H-8), 7.42 – 7.36 (2H, m, H-3`, 5`), 7.19 – 7.11 (2H, m, H-
6, 4`), 6.32 – 5.61 (1H, m, H-9/9`), 3.73 – 3.67 (4H, m, H-2``, 5``/3``, 6``), 3.59 (2H, dd, J 
10.7, 5.8 Hz, H-10), 3.45 – 3.12 (1H, m, H-9/9`), 2.58 (2H, t, J 5.8 Hz, H-11), 2.50 – 2.44 (4H, 
m, H-2``, 5``/3``, 6``); 13C NMR (101 MHz, CDCl3) δC 158.7 (C-q), 158.3 (C-q), 151.2 (C-q), 
138.7 (C-q), 133.4 (C-7), 129.0 (C-3`, 5`), 125.1 (C-8), 124.3 (C-6/4`), 122.0 (C-6/4`), 121.8 
(C-2`, 6`), 121.0 (C-5), 111.0 (C-q), 67.1 (CH2 ×2), 57.8 (C-11), 53.6 (CH2 x2), 38.1 (C-10); 
















4-Bromoaniline (0.11 g, 0.64 mmol, 1.3 eq) was reacted with compound 4 (0.10 g, 0.51 mmol) 
for the synthesis of 18, which was purified by recrystallisation from boiling MeOH and 
obtained as a white solid (0.11 g, 64%), m.p. 150-151 °C, Rf = 0.65 (MeOH/DCM, 8:92). 1H 
NMR (400 MHz, DMSO) δH 9.22 (1H, s, H-9), 8.18 (1H, q, J 4.4 Hz, H-10), 8.03 (1H, dd, J 
8.4, 1.2 Hz, H-5), 7.97 – 7.88 (2H, m, H-3`, 5`), 7.59 (1H, td, J 8.3, 1.3 Hz, H-7), 7.48 – 7.38 
(3H, m, H-2`, 6`, 8), 7.19 (1H, td, J 8.3, 1.3 Hz, H-6), 3.04 (3H, d, J 4.4 Hz, H-11); 13C NMR 
(101 MHz, DMSO) δC 160.6 (C-q), 156.5 (C-q), 150.2 (C-q), 140.8 (C-q), 132.5 (C-7), 130.9 
(C-2`, 6`), 125.0 (C-8), 122.6 (C-5), 121.7 (C-6), 120.5 (C-3`, 5`), 111.8 (C-q), 27.8 (C-11); 
















33% Methylamine in ethanol (0.11 mL, 0.85 mmol, 1.1 eq) was reacted with compound 4 (0.15 
g, 0.78 mmol) for the synthesis of 19, which  was purified by flash chromatography, Rf = 0.5 
(MeOH/DCM, 12:88), and obtained as a white solid (0.13 g, 92%), m.p. 124-125 °C. 1H NMR 
(400 MHz, DMSO) δH 7.90 (1H, dd, J 8.1, 1.0 Hz, H-5), 7.74 – 7.66 (1H, m, H-9`), 7.46 (1H, 
td, J 8.1, 1.0 Hz, H-7), 7.27 (1H, dd, J 8.1, 1.0 Hz, H-8), 7.01 (1H, td, J 8.1, 1.0 Hz, H-6), 6.28 
– 6.15 (1H, m, H-9), 2.97 (3H, d, J 3.8 Hz, H-10`), 2.88 (3H, d, J 3.8 Hz, H-10); 13C NMR 
(101 MHz, DMSO) δC 160.2 (C-q), 159.5 (C-q), 151.0 (C-q), 131.6 (C-7), 124.1 (C-8), 122.2 
(C-5), 119.5 (C-6), 111.0 (C-q), 27.5 (C-CH3), 27.1 (C-CH3); HRMS (ESI) m/z: Found 
















4-Ethoxy aniline (0.13 mL, 1.0 mmol, 2 eq) was reacted with compound 2 (0.10 g, 0.50 mmol, 
1 eq) for the synthesis of 20. Compound 20 was purified by flash column chromatography, Rf 
= 0.4 (MeOH/DCM, 8:92), recrystallised from boiling methanol and obtained as a light brown 
solid (0.205 g, 64%), m.p. 69-70 °C. 1H NMR (400 MHz, DMSO) δH 9.41 (1H, s, H-9/ 9`), 
8.83 (1H, s, H-9/ 9`), 8.32 (1H, dd, J 8.3, 1.3 Hz, H-5), 7.72 – 7.69 (4H, m, H-Ar), 7.61 (1H, 
td, J 8.3, 1.3 Hz, H-7), 7.41 (1H, dd, J 8.3, 1.3 Hz, H-8), 7.21 (1H, td, J 8.3, 1.3 Hz, H-6), 6.99 
– 6.89 (2H, m, H-Ar), 6.85 – 6.75 (2H, m, H-Ar), 4.05 (2H, q, J 7.0 Hz, H-7`/7``), 3.98 (2H, q, 
J 7.0 Hz, H-7`/7``), 1.35 (3H, t, J 7.0 Hz, H-8`/8``), 1.31 (3H, t, J 7.0 Hz, H-8`/8``); 13C NMR 
(400 MHz, DMSO) δC 158.4 (C-q), 156.7 (C-q), 154.9 (C-q), 153.0 (C-q), 151.8 (C-q), 134.3 
(C-q), 132.6 (C-7), 132.3 (C-q), 125.3 (C-8), 124.3 (C-Ar ×2), 122.9 (C-5), 121.2 (C-6), 120.5 
(C-Ar ×2), 114.2 (C-Ar ×2), 114.1 (C-Ar ×2), 111.6 (C-q), 63.1 (C-CH2), 63.0 (C- CH2), 14.7 
(C-CH3), 14.7 (C-CH3); HRMS (ESI) m/z: Found 401.1980. Calculated 401.1978, C24H25N4O2 
















4-amino-1-boc-piperidine (0.23 g, 1.2 mmol, 1 eq) was reacted with compound 6 (0.30 g, 1.2 
mmol) for the synthesis 21, which was purified by flash chromatography, Rf = 0.7 
(EtOAc/Hexane, 30:70), followed by recrystallisation from boiling methanol and obtained as 
a white solid (0.28 g, 85%), m.p. 106-107 °C. (400 MHz, DMSO) δH 9.34 (1H, s, H-9`), 8.28 
(1H, dd, J 7.9, 1.1 Hz, H-5), 7.93 (2H, d, J 8.1 Hz, H-2`, 6`), 7.55 (1H, td, J 7.9, 1.1 Hz, H-7), 
7.36 (2H, t, J 8.1 Hz, H-3`, 5`), 7.31 (1H, dd, J 7.9, 1.1 Hz, H-8), 7.13 (1H, td, J 7.9, 1.1 Hz, 
H-6), 7.08 (1H, t, J 8.1 Hz, H-4`), 6.78 – 6.56 (1H, m, H-9), 4.03 – 3.95 (3H, m, H-1``, H-
CH2), 2.92 – 2.86 (2H, m, H-CH2), 1.94 – 1.80 (2H, m, H-CH2), 1.41 (9H, s, H-12), 1.39 – 1.32 
(2H, m, H-CH2); 13C NMR (101 MHz, DMSO) δC 158.1 (C-q), 153.9 (C-q), 152.5 (C-q), 139.7 
(C-q), 132.5 (C-7), 128.3 (C-3`, 5`), 124.9 (C-8), 123.0 (C-4`/5), 122.9 (C-4`/5), 121.6 (C-2`, 
6`), 120.3 (C-6), 78.5 (C-q), 47.5 (C-1``), 42.5 (CH2 ×2), 31.7 (CH2 ×2), 28.1 (C-12); HRMS 















N-Methylaniline (0.060 mL, 0.55 mmol, 1 eq) was reacted with compound 7 (0.15 g, 0.56 
mmol) for the synthesis 22, which was purified by flash chromatography, Rf = 0.4 
(EtOAc/Hexane, 30:70), followed by recrystallisation from boiling methanol and obtained as 
a white solid (0.14 g, 73%), m.p. 112-113 °C. 1H NMR (400 MHz, DMSO) δH 7.48 – 7.43 (2H, 
m, H-2`, 6`), 7.42 – 7.35 (6H, m, H-3`, 3``, 5, 5`, 5``, 7), 7.30 – 7.24 (1H, m, H-4``), 7.21 – 
7.14 (3H, m, H-2``, 4`, 6``), 6.85 – 6.80 (1H, m, H-8), 6.74 – 6.68 (1H, m, H-6), 3.60 (3H, s, 
H-9/9`), 3.32 (3H, s, H-9/9`); 13C NMR (101 MHz, DMSO) δC 161.3 (C-q), 157.5 (C-q), 153.4 
(C-q), 147.9 (C-q), 145.6 (C-q), 131.6 (C-5), 129.5 (C-3``, 5``), 127.9 (C-3`, 5`), 125.9 (C-7), 
125.8 (C-2`, 6`), 125.7 (C-4``), 125.7 (C-8), 125.3 (C-2``, 6``), 124.1 (C-4`), 120.1 (C-6), 111.8 
(C-q), 41.4 (C-9`), 37.5 (C-9); HRMS (ESI) m/z: Found 341.1768. Calculated 341.1766, 
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Appendix A  
 
CheckCIF/PLATON report  
Structure factors have been supplied for data block(s) c2c 
THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE 
FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED 
CRYSTALLOGRAPHIC REFEREE. 
No syntax errors found.        CIF dictionary        Interpreting this report 
Data block: c2c  
 
Bond precision: C-C = 0.0035 A Wavelength=0.71073 
Cell: 
a=30.523(5) b=6.7975(12) c=19.261(3) alpha=90 beta=127.608(3) 
gamma=90 
Temperature:  173  K  
 
Calculated Reported 
Volume 3165.9(9) 3165.8(9) 
Space group C 2/c  C 1 2/c 1  
Hall group -C 2yc  -C 2yc  
Moiety formula 
2(C14 H16 Cl N3), 2(C H4 
O), H2 O 
0.2(C14  H16 Cl N3), 0.1(H 2 
O), 0.2(C H4 O) 
Sum formula C30 H42 Cl2 N6 O3 
C3 H4.20 Cl0.20 N0.60  
O0.30 
Mr 605.60 60.56 
Dx,g cm-3 1.271 1.271 
Z 4 40 
Mu (mm-1) 0.245 0.245 
F000 1288.0 1288.0 
F000’ 1289.62  
h,k,lmax 40,9,25 40 ,9, 25 
Nref 4073  4054  
Tmin,Tmax 0.963,0.983 0.620,0.746 
Tmin’ 0.957  
Correction method= # Reported T Limits: Tmin=0.620 Tmax=0.746 
AbsCorr = MULTI-SCAN 
Data completeness= 0.995 Theta(max)= 28.667 
R(reflections)= 0.0481( 2938) wR2(reflections)= 0.1453( 4054) 
S = 1.039 Npar= 192 
                                                      Supplementary Data  
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